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Abstract
MATHEMATICAL MODELS OF INFECTION PREVENTION PROGRAMS IN
HOSPITAL SETTINGS
By Kelly A. Reagan
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy, Systems Modeling and Analysis at Virginia Commonwealth
University.
Virginia Commonwealth University, 2022.

Advisor: David M. Chan, Ph.D.,
Associate Professor, Department of Mathematics and Applied Mathematics
Hospitals play a vital role in providing for the healthcare needs of a community.
Patients can develop hospital-acquired infections (HAIs) during their hospitalization
due to exposure to foreign bacteria, viruses, and fungi. Infection prevention programs
target and reduce HAIs, but implementing the infection prevention programs often
comes with a cost. The goal of my research is to use mathematical models to quantify
the impact of infection prevention programs on cases of HAIs and total healthcare
costs. First, I use a Markov chain model to quantify how one infection prevention
program reduces general HAIs in the hospital. Then, I calculate the impact of resistance by healthcare leaders to implement two infection prevention techniques on two
HAIs in the hospital. I used ordinary differential equations to quantify the timing
of initiation and termination of two infection prevention programs within a region
divided into two components to understand how a community intervention and a localized intervention affect the peak number of infections in an epidemic. Finally, I
viii

used an agent-based model to quantify the impact of one specific infection prevention
program on one HAI in one ward within the hospital. Overall, my research supports
implementing the specific infection prevention programs examined to reduce the burden on healthcare systems and improve patient outcomes.

ix

CHAPTER 1

INTRODUCTION

Mathematical epidemiology focuses on modeling infectious diseases to better understand the causes, predict the spread, determine ways to control the spread and simulate how various disease prevention programs may affect the disease’s impact on a
community. A specific set of infections, hospital-acquired infections (HAIs), are infections that a patient develops during their stay at the hospital. Because a patient is
not often admitted with an HAI, it is important to prevent HAIs with proper infection
prevention programming to reduce the patient’s length of stay, overall morbidity, mortality and healthcare costs. My research focuses on quantifying the potential impact
of infection prevention programs on HAIs.
I employ mathematical models to fit the settings and conditions within the hospital. My process includes identifying model variables, parameters, estimating the
costs of the prevention program as well as the costs of the infection, and providing
conclusions targeted towards healthcare leaders to inform best practices.
Mathematical modeling allows me to perform studies on HAIs in silico. The
experiments that I simulate often cannot be done in a clinical setting due to ethical
standards of treatment. Because of this, precise parameter values are unknown and
have to be estimated through simulations. The results from the mathematical models
provide general trends for complicated problems. The mathematical simulations are
low cost, provide quick results, are easily modifiable and have defined control and
treatment groups.
HAIs affect about one in 25 hospitalized patients and are largely preventable
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[Johnson et al., 2014, Magill et al., 2014, Bearman et al., 2019]. In 2001, HAIs were
one of the leading causes of death in the United States [Wenzel and Edmond, 2001].
Cases of HAIs declined from 2015 until 2020 due to successful infection prevention
and control policies enforced by the Centers for Disease Control and Prevention’s
(CDC) National Healthcare Safety Network. Unfortunately, due to the COVID-19
pandemic and the subsequent stress placed on healthcare facilities, HAI incidence has
increased since the pandemic began in late 2019 [Weiner-Lastinger et al., 2022]. This
highlights the importance of maintaining the effectiveness of HAI prevention practices
even when public health emergencies arise [Weiner-Lastinger et al., 2022].
Revelas [2012] broadly defines HAIs to be infections “acquired in the hospital or
healthcare service unit that first appear 48 hours or more after hospital admission
or within 30 days after discharge of patient care”. Some HAIs include “catheterassociated urinary tract infections, central line-associated bloodstream infections, surgical site infections, ventilator-associated pneumonia, hospital-acquired pneumonia,
and Clostridioides difficile infections” [Monegro et al., 2017]. The CDC provides
context for the morbidity of HAIs in the United States in Table 1.
Major Site of Infection

Estimated Number

Pneumonia

157,500

Gastrointestinal Illness

123,100

Urinary Tract Infections

93,300

Primary Bloodstream Infections

71,900

Surgical site infections from any inpatient surgery

157,500

Other types of infections

118,500

Estimated total number of infections in hospitals 721,800

Table 1 : HAI Estimates Occurring in US Acute Care Hospitals, 2011 [Centers for
Disease Control and Prevention, 2018]

HAIs are most frequently caused by viruses, bacteria and fungal pathogens. Mon2

itoring and treating HAIs has become increasingly more difficult because patients are
being discharged from the hospital sooner than ever due to medical and technological
advances [Collins, 2011]. HAIs also continue to challenge healthcare systems due to
increasing bacterial and antibiotic resistance [Revelas, 2012].
The World Health Organization suggests that HAIs continue to plague even
the most advanced hospitals. This is due to the fact that medical devices and patient wounds provide access for external bacteria to enter the patient’s body. Also,
drug-resistant bacteria make it difficult for patients to be treated under traditional
preventative practices [Serra-Burriel et al., 2020].
Mortality rates, length of patient stay in the hospital and cost are much higher
for patients with HAIs than patients without HAIs [Glance et al., 2011]. Further, the
total cost of the hospital stay is about “2.6 to 6 times higher in patients with HAI
compared with patients without HAIs” [Glance et al., 2011], and they cost about
$45,000 on average [Dancer, 2014].
HAIs are largely preventable when effective infection prevention strategies are
sustainably implemented and followed at high compliance levels [Bearman et al.,
2019]. These prevention strategies often include improving catheter insertion techniques, following contact precautions, monitoring hand hygiene, disinfecting caps for
IV lines and bathing patients, especially near the site of device insertion. These often
prevent and reduce HAIs from developing or worsening [Bearman et al., 2018, Climo
et al., 2013]. Healthcare institutions need to have effective leadership and access to
information on infection control practices in order to sustain best practices [Bearman
et al., 2019].
In summary, prior research indicates that HAIs are a burden to healthcare systems and infection intervention strategies can prevent HAIs from developing. In the
following chapters I develop and utilize mathematical models to quantify the impact
3

of infection prevention strategies on yearly HAIs and the associated costs. Providing
estimations on the number of cases of HAIs and potential savings related to the timing and effectiveness of implementing the program allows healthcare leaders to make
decisions on whether or not the infection prevention program should be incorporated
into their standard practices.
In Chapter 2, I first examine how CHG bathing, an infection intervention program, affects general HAIs. This was done using a Markov chain model examining
different levels of compliance in CHG bathing, and then measuring the effects on
the number of HAIs and associated costs. I also examine the effects of the delay
in implementing infection prevention strategies that can occur at the administrative
level of a hospital. Here, I employ a Markov chain model to quantify implementing
CHG bathing at 10% incremental compliances, and examine how the delay in starting
CHG bathing and using a standardized central line bundle kit affects cases of centralline bloodstream infections (CLABSI) and catheter-associated urinary tract infections
(CAUTI). I also look at costs associated with treating HAIs and implementing these
programs.
In Chapter 3, I quantify the interplay of implementation and termination of
different infection prevention strategies during a pandemic. The research was inspired
by the beginning of the COVID-19 pandemic when healthcare workers did not have
enough personal protective equipment (PPE) to adequately keep them safe from
the transmission of the virus in addition to social distancing being introduced and
enforced in the community. I used a Susceptible-Infected-Recovered (SIR) Model,
which is a system of ordinary differential equations, to model the dynamics of the
two infection prevention techniques and how they affect the timing and the size of
the peak number of infections during the outbreak.
In Chapter 4, I simulate implementing a specific infection intervention program
4

in efforts to reduce the incidence of Clostridiodes difficile infections (CDIs) in only
the Bone Marrow Transplant (BMT) unit within a hospital. I use an agent-based
model (ABM) to quantify how testing a patient for Clostridiodes difficile (C. diff )
before the patient is admitted to the BMT Unit affects the number of cases of CDI.
The process of testing a patient for C. diff before admission is called active detection
and isolation (ADI). I quantify the impact of implementing ADI on the number of
community-acquired and hospital-acquired cases of CDI. I also calculate the costs
associated with implementing ADI, and compare it to the cost of not using ADI as
an infection prevention practice.

5

CHAPTER 2

CHLORHEXIDINE GLUCONATE BATHING AND A
STANDARDIZED CENTRAL LINE BUNDLE KIT

2.1

Background
As medical technology has advanced, the use of invasive devices within hospitals

has increased. These invasive devices prolong life but offer foreign entities access
to the body [Kollef et al., 2021]. The use of vascular catheters, such as central vein,
arterial and pulmonary artery catheters can result in a patient developing central lineassociated blood stream infections (CLABSIs). Urinary catheters, such as urethral,
supracubic and percutaneous nephrostomy catheters can cause a patient to develop
catheter-associated urinary tract infections (CAUTIs) [Kollef et al., 2021]. Patients
may also acquire an HAI from being immunocompromised, receiving prophylactic
antibiotics and being exposed to pathogens in the hospital environment [Kollef et al.,
2021].
Prevention strategies are effective in reducing HAIs in hospital units [Glance
et al., 2011]. In an effort to reduce HAIs, studies have been conducted to determine
the effectiveness with bathing patients with an antimicrobial solution, chlorhexidine
gluconate (CHG) [Frost et al., 2016, Rupp et al., 2012]. CHG is a strong antiseptic
because it affects the membrane structure of bacteria, yeasts and viruses [Donskey
and Deshpande, 2016]. Chlorhexidine also is known for having residual antiseptic
effects hours after application, which also makes it favorable in clinical applications
[Donskey and Deshpande, 2016].
To quantify the number of infections that can be prevented by CHG bathing,
6

Climo et al. [2013] and Amirov et al. [2017] conducted clinical studies to estimate
the impact of CHG bathing on the reduction of HAIs compared to the use of soap
and water. Bathing patients with CHG washcloths in prior studies showed that
patients often had adverse skin reactions, but the study by Climo et al. [2013] showed
that patients rarely had adverse skin reactions. Amirov et al. [2017] focused on
determining the effect of CHG bathing in hospital units where patients stayed for
months and years rather than days. They also concluded the CHG bathing reduces
the incidence of HAIs.
In a meta-analysis study, Frost et al. [2016] estimated the reduction of HAI
risk with daily CHG CLABSI, vancomycin-resistant Enterococcus (VRE), CAUTI,
Methicillin-resistant Staphylococcus aureus (MRSA), ventilator-associated pnuemonia (VAP), and CDI. They reported a 56% decreased risk of CLABSI, 37% decreased
risk for VRE, 7% decreased risk of CAUTI, 36% decreased risk of MRSA bacteraemia,
18% decreased risk of VAP, and a 7% decreased risk of CDI with daily CHG bathing.
In addition, Huang et al. [2016] conducted a meta-analysis study on CHG data and
reported a 32% decreased risk of acquiring CAUTI.
Another method of improving patient outcomes with central lines is using a
standardized central line bundle kit. This kit includes all of the materials needed
to insert a central line, including the supplies to clean the patient with CHG, in
addition to the educational material for healthcare workers to reference in order to
maximize the success of the insertion [McMullan et al., 2013]. The alternative is
that a healthcare professional would gather the supplies themselves and remember
the process of inserting a central line [Fenik et al., 2013].
The use of a standardized central line bundle kit is one infection prevention
program that has proven to reduce CLABSIs [McMullan et al., 2013, Lee et al., 2018].
The wards of the hospital with the lowest central line kit utilization had the highest
7

rate of CLABSI, and the ward with the highest utilization of the kit had the lowest
rate of CLABSI. Fenik et al. [2013] found that healthcare workers spent less time
and wasted fewer materials with the bundled kit than if they obtained the materials
together themselves. Upon implementation of the standardized central line bundle
kit, McMullan et al. [2013] saw a 59% decrease in CLABSI cases over a five-year
period. Allen et al. [2014] also reported a decrease in CLABSIs from 2.72 per 1,000
catheter-days before the intervention to 0.40 per 1,000 over the 37 months following
intervention when the standardized kit was incorporated into the care of patients
within the ICUs of Fletcher Allen Hospital in Vermont.
CLABSIs and CAUTIs are largely preventable with proper education and maintenance of the patient’s device under the care of the patient’s healthcare team [MacEwan et al.]. According to Magill et al. [2014], 4% of all hospitalized patients had at
least one HAI at the time of their research. In the same study, CAUTIs accounted for
12.9% of all HAIs and CLABSIs accounted for 9.9% of all HAIs [Magill et al., 2014].
However, research by Agency for Healthcare Research and Quality [2019] supports
CAUTI (32%) and CLABSI (14%) accounting for 46% of all HAIs.
Although CHG bathing and implementing a standardized central line bundle
kit have clinical research support to improve patient outcomes, successful prevention
practices are not always put into practice. New practices or improvement of current
practices may be rejected by “active resistors”, individuals in healthcare leadership
positions who can stop initiatives before they start, and by “organizational constipators”, healthcare leaders who slow the implementation of a new practice. The
ideas may be rejected because infection prevention initiatives may directly contradict
mandates given to other divisions, such as reducing supply costs per patient days.
Resistance can create unnecessary delays that have large ramifications for patient
outcomes as well as the health system’s overall fiscal health.
8

The goal of this chapter is to quantify the costs and predict the number of preventable HAIs associated with the quality and timing of two infection prevention
programs. More specifically, I examine how the compliance level of CHG bathing
affects annual rates of HAIs and their costs. Additionally, I calculated the number of
preventable CLABSI and CAUTI cases and their associated costs when the standardized central line bundle kit and CHG bathing are not immediately put into the routine
practice of caring for patients with urinary catheters, central lines, when healthcare
leaders delay implementing these prevention practices.
2.2

Mathematical Modeling with Markov Chains, HAIs Prevented and
Money Saved
Here, the objective is to track a patient’s status throughout their stay in the

hospital to keep track of a patient’s infection status, whether or not they receive the
infection intervention program, and whether they are being admitted or discharged.
I note that the timing of events during their stay influence a patient’s probability
of developing an infection. A Markov chain model was used because infections are
probabilistic in nature. So, the outcome for an individual patient is only determined
by these probabilities that they received a device, or acquired an infection.
2.2.1

Markov Chain Modeling the Reduction of HAIs with CHG Bathing

A Markov chain model is a mathematical modeling technique consisting of various
compartments and the probabilities of transitioning into another compartment. The
compartments are chained together with directed pathways where one compartment
can transition into another compartment as seen in Figure 1. The current state of the
system depends on the conditional probability that an event occurred at the previous
time step. I use a discrete Markov chain model where each time step is a single day.
9

The model incorporates the classes of patients and the daily probabilities that
a patient was bathed, discharged or infected. In Figure 1, patient compartments or
states are depicted by black boxes and the transitions between the compartments are
denoted by the colored arrows. Nj (j = 0, 1, 2) are patients who have not been CHG
bathed or become infected. Pj (j = 0, 1, 2, 3) are patients who received a CHG bath
j days ago. Patients who have an HAI are in PI .
The CHG bathing bathing compliance is the daily probability that a patient will
receive a CHG bath, and is represented by the blue arrows. When a patient received a
CHG bath, they transition into the P0 class, meaning that the patient just received a
CHG bath. The red arrows are the probabilities of being discharged. When a patient
is discharged, a new patient is admitted into N0 . The likelihood of getting an HAI is
denoted by the yellow arrows.
When a patient gets an HAI, they move into the PI class where they remain for
the rest of their stay. Finally, if a patient is not bathed, discharged, or infected with
an HAI on a given day, the patient moves to the next state in the diagram as denoted
by the green arrows.
The green arrows transition patients into the j + 1 state from where they were
previously, except for patients in terminal states of N2 and P3 . Without receiving a
CHG bath, getting an HAI or being discharged, patients in N2 transition into P3 and
patients in P3 remain in P3 . This is because a patient’s microbiome regenerates after
72 hours, or three days, of injury (such as invasive surgery or an accident) [Howard
et al., 2017]. So, a patient who was admitted to the hospital two days ago and a
patient who received a CHG bath three days ago both have regenerated microbiomes.
However, the probability of getting an HAI is lower for patients in P3 than for patients
in N2 , since they have residual CHG on their skin, which continues to kill bacteria.
The state of the system, A(t), is given by
10

Figure 1 : Markov chain model schematic with all possible patient states and arrows
denoting possible transitions between states.

T


A(t) =

N0 (t) N1 (t) N2 (t) P0 (t) P1 (t) P2 (t) P3 (t) PI (t)

.

To deter-

mine the distribution of patients on day t + 1, I use
A(t + 1) = [B][I][D]A(t),
where D, I and B are transition matrices that represent the probabilities of being
discharged, infected, and bathed for all patient states, respectively. D, the discharge
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matrix, is defined by
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. I, the infection matrix, is defined by
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. B, the CHG bathing matrix, is defined by
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δ is the discharge rate for N0 , N1 , N2 , P0 , P1 , P2 , P3 and δ ′ is discharge rate for PI ,
which was assumed to be lower due to the HAI. ri and ri′ are the infection rates.
Specifically, ri = (1 −

(3−i)α
)r
3

for i = 0, 1, 2, 3 and ri′ = ηri for i = 0, 1, 2, η ∈ [0, 1],

where α is the CHG bathing effectiveness and η is a newly admitted patient’s resistance to infection with their unaltered microbiome. β is the CHG bathing compliance
rate.
The costs associated with giving patients CHG baths are calculated based upon
the number of patient baths given, and is calculated by tracking the number of patients who entered P0 at every time step. The number of HAIs are calculated by
counting all of the patients who entered PI . The total cost calculation include costs
related to bathing materials and the costs associated with HAIs.
2.2.2

Potential Annual Savings and Prevented HAIs

To quantify the impact of incorporating CHG bathing as an infection prevention
practice, the transition rates in Table 2 are estimated from two years of data from
Virginia Commonwealth University (VCU) Medical Center in Richmond, VA. This
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data includes the average observed incidence rate of 1.025 cases per 1,000 patient days
for CLABSI, CAUTI, and CDI in 2017 and 2018 [Bearman et al., 2018]. VCU Medical
Center recorded an average total of 318 CAUTIs, CLABSIs and CDIs between 2017
and 2018.
The estimated average reduction in the probability of acquiring an HAI due to
CHG bathing, α = 32%, was based on the reductions of risk of HAIs in Frost et al.
[2016] and Huang et al. [2016]. r is calculated with a baseline compliance rate of 60%
and the effect of CHG bathing on the reduction of incidence of CLABSI, CAUTI,
and CDI [Frost et al., 2016, Huang et al., 2016]. The baseline compliance rate of
60% is estimated to be the average compliance rate of CHG bathing followed at VCU
Medical Center.
In order to calculate the costs of implementing CHG bathing, K. Gurney from
VCU Medical Center prices one CHG bath to cost $5.71 (personal communication,
October 18, 2018). Patients who do not receive a CHG bath on a given day were
assumed to receive a bath with non-CHG wipes, which costs $1.16 per bath, as priced
by K. Gurney (personal communication, October 18, 2018). Each specific HAI has
an individual cost to the hospital. On average, I assume an HAI costs the hospital
$45,000 as presented by Dancer [2014].
The simulations were run in Matlab for 100 days before calculating the results
for 365 days at steady state with 850 patients in the hospital. The time step was one
day. Costs were calculated using $5.71 for one CHG bath on one patient, $1.16 for a
non-CHG bath for one patient and $45,000 if a patient got an HAI. If a patient did
not receive a CHG bath, then they received a non-CHG bath. The number of daily
CHG baths, non-CHG baths and HAIs were tracked over one year and the costs were
totaled for each 10% CHG bathing compliance rate.
The results show the impact of increasing the CHG bathing compliance on the
14

Parameter

Symbol

Value

Daily probability of infection

r

0.00134 (32% effectiveness)

CHG bathing effectiveness

α

0.32 HAIs per day

Unaltered microbiome resistance

η

0.95 per day

Discharge rate for all classes except PI

δ

0.2 patients per day

Discharge rate for PI

δ′

0.1 patients per day

Table 2 : Parameter values used in the Markov chain model simulations with CHG
bathing compliance is increased in 10% increments.

number of HAIs and the amount of healthcare costs saved. In Figure 2, every 10% increase in CHG bathing compliance results in about 10 HAIs prevented. Additionally,
Figure 3 shows that every 10% increase in CHG bathing compliance would result in
about $450,000 saved per year.
Assuming 90% is an attainable compliance rate to reach, increasing the CHG
bathing compliance from 60% to 90% incurs an additional cost of $106,291.65 spent
on CHG bathing wipes. However, at 32% reduction in HAI incidence, increasing the
compliance rate from 60% to 90% results in 20 averted infections and $815,301.75
saved cost. Further, based on the HAI mortality rate of 15%-25%, approximately 5
lives will be saved [O’Horo et al., 2012].
2.2.3

Markov Chain Modeling and the Timing of Implementing Infection
Prevention Programs

Unfortunately, it is not always straightforward to change hospital practices. Active resistors and organizational constipators are individuals in leadership positions
who block change, delay adoption of best practices, and inhibit new prevention protocols from being implemented in hospital systems. A strategy to overcome active
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Figure 2 : The decrease in yearly HAIs
Figure 3 : The increase of overall savat 32% reduction in incidence due to ings with a 32% reduction in incidence
CHG bathing with an increase in CHG due to CHG bathing by increasing CHG
bathing compliance.
bathing compliance from 0%.

resistors is to present data and scientific evidence supporting a new practice over the
current practice.
To quantify the impact of active resistors and organizational constipators, the
Markov chain model is expanded to focus on the delay of implementation of CHG
bathing and the use of the standardized central line bundle kit, and examine this
delayed effect on CLABSIs and CAUTIs. Patient compartments are modified to include patients with urinary Foley catheters (foleys), central lines, both and neither
devices. CHG bathing reduces incidence of CLABSI and CAUTI because of its antimicrobial properties that fight harmful bacteria [Donskey and Deshpande, 2016].
The standardized central line bundle kit reduces incidence of CLABSI because it provides everything that a healthcare worker needs in order to successfully and sanitarily
insert a central line [McMullan et al., 2013, Lee et al., 2018].
In this model, there are different patient types: newly admitted patients without
a central line or foley, N , patients without a central line or foley and are not newly
admitted, O, patients with a central line and have not received a new central line
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with the standardized kit in i days (i = 0, 1, 2, 3), Ci , patients with a foley and have
not had a CHG bath in i days (i = 0, 1, 2, 3), Fi , and patients with both a central line
and a foley and have not received wither a new central line or a CHG bath in i days
(i = 0, 1, 2, 3), Ti . It is assumed that the effectiveness of the intervention program
decreases each day until i = 3, when the altered microbiome regenerates [Howard
et al., 2017]. If a patient receives a device during their hospital stay, then they move
to the i = 0 subclass. Patients with central lines may acquire CLABSI, and patients
with foleys may acquire CAUTI. U , B and I patient classes have CAUTI, CLABSI
or both CAUTI and CLABSI respectively. Patient compartments are denoted by the
black boxes in Figure 4.
Patients with CLABSI or CAUTI may develop a secondary infection of the other
type. Patients may also acquire both infections within the same day. Additional
infections beyond acquiring CAUTI and CLABSI are not considered. If a patient
acquires an infection, their transition is denoted by the red arrows in Figure 4. If a
patient does not acquire a new infection or utilize a new intervention, then the patient
moves to the i + 1 version of the same class, as they did in the general HAI Markov
chain model. If the patient has an infection or is within the circulating class, O, the
patient stays within their class as indicated in Figure 4 by the purple arrows. If a
patient is discharged, as indicated by the green arrows, then a new patient is admitted
into N . If a patient gets a device, then they move into C, T or F as indicated by the
gold arrows.
The distribution of patients in each class at each time step, t (number of days),
is given by the state vector
X(t) = [N (t), O(t), C0 (t), C1 (t), C2 (t), C3 (t), F0 (t), F1 (t), F2 (t), F3 (t), ...
T0 (t), T1 (t), T2 (t), T3 (t), B(t), U (t), I(t)].
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Figure 4 : A flow diagram of the model. The gold arrows, ρp , indicate a patient getting
a device. The red arrows, r, show patients acquiring an infection. The green arrows,
δw , are patients being discharged. The purple arrows are the patients’ progression
through the diagram if the patient does not receive any actions.

The distribution of patients on day t + 1 is defined by the state vector X(t + 1) =
[B ∗ ][I ∗ ][P ∗ ][D∗ ]X(t), where B ∗ , I ∗ , P ∗ , and D∗ are transition matrices. In particular
B ∗ represents patients receiving a CHG bath or obtaining a new standardized central
line kit. I ∗ represents the probability of patients getting an infection. P ∗ represents
the probability of getting a central line or foley, and D∗ is the transition matrix for
being discharged.
The patient’s average length of stay,

1
,
δw

differs for each class w. The daily

probability of getting an intervention p, ρp , is calculated using, ρp = 1 − (1 − K)δw ,
where K represents the percentage of hospitalized patients with intervention p. It is
assumed that getting a catheter and getting a central line are independent events.
The infection rate, r, is calculated with a baseline compliance rate of 60% CHG
bathing and with the pre- and post-intervention values of the standardized kit. The
reduction of incidence of CAUTI and CLABSI due to CHG bathing is represented by
η. The reduction of CLABSI due to the standardized kit is represented by κ. The
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equation for r for those with central lines or both devices is ri = (1 −

(3−i)ηκ
)r
3

for

(3−i)η
)r
3

for

(i = 0, 1, 2, 3). The equation for r for patients with catheters is ri = (1 −

(i = 0, 1, 2, 3). Chlorhexidine’s antimicrobial agents can last on the skin for up to 48
hours and it is assumed that the effectiveness of the CHG reduced the longer it has
been on the skin, which is why the infection rate increases with each day since the
patient received a CHG bath or since the patient was first admitted [Ilango et al.,
2013, Donskey and Deshpande, 2016].
2.2.4

Number of CLABSIs, CAUTIs and Total Cost Due to Delaying
Best Practices

Overall, I calculate the impact of active resistors and organizational constipators
on yearly CLABSIs and CAUTIs by looking at the changes to annual number of HAIs
and associated costs. In the Markov chain model, I estimate the values for ri , rk , η, κ
and r (see Table 3 for values) by running simulations to mimic data from VCU Medical
Center before both interventions. The parameters η and κ were estimated based
upon the reduction of incidence of the infection prevention programs on CLABSI
and CAUTI. Prior to the standardized central line bundle kit and CHG bathing
interventions, there were 80 CLABSI and 39 CAUTI infections annually at VCU
Medical Center. The probability of a patient developing CAUTI was 0.1257 per 1000
patient days and 0.2579 per 1000 patient days for CLABSI. The simulations were run
in Matlab R2018b with time steps of one day. The results are based on simulations
run for 100 days to reach steady state and then calculated for 365 days with 850
patients.
The Markov chain model simulations were run with parameter values associated
with patients with central lines and foleys. The specific values from literature used
to calculate δw and ρp are presented in Table 3, which also contains the calculation
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for the infection rates, r.
Monetizing the impact of the delay of infection prevention programs on CLABSIs and CAUTIs includes costs related to CHG bathing materials for CAUTI, the
standardized central line bundle kit for CLABSI, and the costs associated with HAIs.
The costs used in this project are different from the previous project because they
were updated at the time of completing the project. In this study, the updated cost
for one CHG bath costs $8.47 (US dollars). Patients that do not receive a CHG
bath on a given day were assumed to receive a bath with non-CHG wipes that cost
$2.47 per bath. The non-centralized central line bundle costs $0.04 more due to the
compilation of necessary supplies needed to insert a central line compared to the
standardized central line bundle kit. On average, I assumed that a CAUTI infection
costed $13,793 [Agency for Healthcare Research and Quality, 2017] and a CLABSI
infection costed $70,696 [Agency for Healthcare Research and Quality, 2013]. The
total cost calculation includes the number of CHG baths given, the number of nonCHG baths given, the number of standardized central line bundle kits used and the
costs associated with getting CAUTI and CLABSI over one year.
Implementation of CHG bathing and the standardized central line bundle kit,
and the associated costs, are simulated to be initiated in increments of six-month
delays, and compared to no implementation over 5 years. Simulations were run for
the desired delay amount without either infection prevention program, then once
the time delay was reached, the programs were implemented hospital-wide at 100%
compliance. Overall, as the delay in implementation for the infection intervention
programs increases, the number of HAIs increases as seen in Figure 5, and the associated savings in healthcare costs by implementation decreases seen in Figures 6 and 7.
When a linear trend line is fit to the results, every six-month delay in improvement of
CHG bathing compliance results in about 11 preventable CAUTIs and an additional
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Parameter
Discharge rate for patients
with central lines
Discharge rate for
patients with CAUTI
Discharge rate for patients with
central lines and catheters
Discharge rate for
patients with CLABSI
Discharge rate for patients
with catheters
Discharge rate for all other
patients in the hospital
Probability of getting a central line
Probability of getting a catheter
Probability of getting both a
central line and a catheter
Actual infection rate for
those who have received a
central line or both devices in i days
Actual infection rate for
those who have
received a catheter k days ago
Reduction of incidence of CAUTI
and CLABSI due to CHG bathing
Reduction of CLABSI due to the
standardized kit
Base infection rate for
patients with central lines or
both devices
Base infection rate for
patients with catheters

Parameter
Symbol

Parameter
Value

Source

δCL

0.0556

[Dube et al., 2020]

δCAU T I

0.0556

[Al-Hazmi, 2015]

δboth

0.0556

[Dube et al., 2020]

δCLABSI

0.0417

[Dube et al., 2020]

δCAT H

0.1

[Al-Hazmi, 2015]

δOther

0.2

[Baek et al., 2018]

ρCL
ρCAT H

0.01232
0.01270

ρBoth

1.565*10−4

[Chopra et
[Carrouget
[Chopra et
[Carrouget

ri

(1 −

(3−i)(η+κ)
)r∗
3

Estimated based
upon data

(3−i)κ
3 )r#

Estimated based
upon data

(1 −

rk

al., 2014]
et al., 2017]
al., 2014]
et al., 2017]

Estimated based
upon data
Estimated based
upon data

η

0.11

κ

0.49

r∗

4.5*10−9

Estimated based
upon data

r#

1.15*10−10

Estimated based
upon data

Table 3 : Parameter values used in the Markov chain model simulations to quantify
the impact of resistors and constipators on CLABSIs and CAUTIs.
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cost of $11,000. Every six-month delay in implementing the standardized central line
bundle kit results in about 10 CLABSIs and an additional $715,000 in costs.

Figure 5 : Number of infections over five years when the infection prevention program
is delayed by x months. The number of CAUTIs over five years is represented by the
red data points, and the number of CLABSIs over five years is represented by the
blue data points.

2.3

Conclusions
Delaying implementation of infection prevention initiatives leads to increased

HAIs and total associated healthcare costs. If more expensive intervention strategies reduce infections, such as with CHG bathing, the strategies may end up saving
healthcare costs. When the standardized central line bundle kit and CHG bathing
are immediately implemented, healthcare systems comparable to VCU Medical Center can prevent approximately 200 HAIs. Each monthly delay led to decreases in total
associated healthcare savings. There were less overall savings for CAUTI infections
due to the $6.00 difference with the implementation of CHG compared to a $0.04 difference for the standardized central line bundle kit. Also, the healthcare costs dealing
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Figure 6 : Amount of savings over five years when the use of CHG bathing is
delayed by x months. As the number of months to implement the infection prevention
programs increases, the potential cost savings decreases.

with a CAUTI were less than for CLABSI.
The role of active resistors and organizational constipators in implementing CHG
bathing and the standardized central line bundle kit had a dramatic impact on healthcare costs and patient outcomes. The model was limited by the assumptions, such as
not including educational and monitoring costs or considering varying levels of compliance, but allowed for predictions and quantitative analysis of immediate or delay
in implementation of CHG bathing and the standardized central line bundle kit.
Using Markov chain modeling to simulate the impact of CHG bathing and the
standardized central line bundle kit allowed me to estimate results that would have
been otherwise unethical to perform in a clinical setting. Additionally, performing all
of the simulations as clinical studies would have taken years to complete, and would
have required researchers to make sure that other infection intervention programs
23

Figure 7 : Amount of savings over five years when the use of CHG bathing and
the standardized central line bundle kit is delayed by x months. As the number of
months to implement the infection prevention programs increases, the potential cost
savings decreases.

were not introduced during the study period. The mathematical simulations allowed
for the programs to be isolated without confounding variables affecting the results.
With only a few extra dollars spent on each patient, thousands of dollars can
be saved over the span of years. Also, applying the standardized central line bundle
kit and/or CHG bathing to any patient reduces the risk of developing HAIs, which
reduces the amount of time that a patient spends in the hospital. Reducing a patient’s
length of stay allows the hospital to see more patients and reduce healthcare costs.
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CHAPTER 3

FLATTENING THE CURVE

3.1

Introduction
Highly contagious diseases require public health officials to develop and enforce

prevention programs within communities to reduce the burden that these diseases
have. Some highly contagious diseases include norovirus (stomach flu), influenza,
meningitis, hand, foot and mouth disease, pertussis (whooping cough), sexually transmitted infections, Methicillin-resistant staphylococcus aureus (MRSA), tuberculosis
and severe acute respiratory syndrome coronavirus 2 (COVID-19). Some prevention
programs are not resource intensive, such as encouraging people to wash their hands
and to stay home if they are feeling sick. Other programs, such as vaccines, require
extensive research and supplies in order for the programs to be effective in preventing
transmission.
During outbreaks of highly virulent diseases, various intervention strategies may
be implemented to reduce disease spread and “flatten the infection curve.” Flattening
the curve allows for smaller peaks of infections, that are often delayed. This is critical
for the success of healthcare services. Not only do these strategies allow for more time
to prepare for the influx of patients, but caring for a smaller number of patients at
one time prevents healthcare providers and systems from being overwhelmed.
Consider a population broken up into two components: a smaller subset of the
community where an intervention strategy is lost, and large city or small country
where an intervention strategy is implemented. Examples of the smaller subset are
schools, religious centers, healthcare facilities, nursing homes, jails or homeless shel25

ters.
For example, schools could be considered to be a small subset of a community.
Schools may lose a mask mandate that required the faculty and the students to wear
a protective mask during the day. Alternatively, schools may also lose adequate air
circulation or the air quality might be reduced if proper circulation systems cannot
be afforded or if the school has to close windows during the winter. The remainder
of the community, the larger subset, may have to follow a mask mandate when they
are outside of their homes or be required to social distance (maintain at least six feet
apart from other people).
In the example of a community with a large religious organization as the smaller
subset, the religious center may also act as a school, a shelter or a meeting place. The
religious center may lose its ability to keep safe distance between people during large
events or if there was an increased need to shelter people. Then, in the remainder of
the community, the larger subset, a vaccine could be introduced.
My research considers the case of dividing the community into hospitals and
the general population in application to studying a future highly virulent strain of
COVID-19. COVID-19 is a disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) [WHO, 2020]. Common symptoms are respiratory infections, fever and dry cough [WHO, 2020]. Patients usually develop symptoms within
twelve days [Lauer et al., 2020]. The virus is contracted from other infectious individuals from direct contact with mouth or nose droplets [WHO, 2020], and from a
person touching an infected object or surface [Lauer et al., 2020].
One COVID-19 prevention program is social distancing. Social distancing involves maintaining a minimum of six feet between people and is recommended to
help stop the spread of the virus. It is not resource-intensive and is effective in reducing the spread of COVID-19 [Nanotkar et al., 2020]. Caley et al. [2008] showed that
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social distancing was effective during the Spanish Influenza of 1918. Approximately
260 per 100,000 lives were likely saved as a result of social distancing [Caley et al.,
2008]. Social distancing is critical in preventing infections when there exist asymptomatic carriers within a community [Whitehead and Feibel, 2020, Wilder-Smith and
Freedman, 2020].
Another infection prevention program that reduces the transmission of many infections is the use of personal protective equipment (PPE). The Occupational Safety
and Health Administration recommends that all healthcare workers protect themselves with PPE when interacting with infectious patients. PPE are any pieces of
equipment worn in order to reduce injury or illness due to hazards in the workplace
[OSHA, 2020]. In the specific case of studying COVID-19, goggles or face shields,
facemasks and gloves are all recommended by the CDC as PPE to prevent the transmission of the virus [Centers for Disease Control and Prevention, 2020]. Contact
precautions or airborne precautions (depending on the patient) and eye protection
should all be utilized to prevent the spread of the virus [OSHA, 2020], as well as standard precautions like washing hands. The demand for PPE increases as COVID-19
becomes more prevalent.
This research focuses on the timing of initiation and termination of social distancing in the general community and PPE use in hospitals, and how these affect
the total number of COVID-19 cases. Previous studies reported combinations of disease control methods are most effective in reducing the transmission of COVID-19
[Patiño-Lugo et al., 2020, Nussbaumer-Streit et al., 2020]. Additionally, assuming
early control of the epidemic, I considered the results of removing social distancing
restrictions. Overall, I analyzed the impact of these intervention strategies on the
total number of infections on a scale of a small country.
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Figure 8 : SIR model diagram with transition rates β(t) and d1 .

3.2

Mathematical Modeling
The focus on this study is to examine the effect of the removal and start of

intervention strategies. In particular the implementation of social distancing on the
general public, and the loss of PPE in healthcare facilities. To accomplish this, I use a
simple Susceptible-Infected-Recovered (SIR) model with a time-dependent infection
rate, β(t). The model to calculate the total number of COVID-19 cases is given by,
dS
= −β(t)SI
dt
dI
= β(t)SI − d1 I
dt
dR
= d1 I,
dt

(3.1)

where d represents the length of time individuals remain infectious.
The infection rate, β(t), is defined to be
β(t) = β1 (t)H + β2 (t)(1 − H),

(3.2)

where H is the weighted proportion of the infection rate parameter that is due to the
infections within the hospital. β1 and β2 are defined as


 βh Eh ,
t ≤ Th
β1 (t) =
,

 βh ,
t > Th
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(3.3)

and

β2 (t) =



 βs ,

t ≤ Ts


 βs Es ,

t > Ts

,

(3.4)

where βh and βs are the base infection rates in the hospital setting and outside
hospitals, respectively. Eh is the effectiveness of PPE in hospitals, and Es is the
effectiveness of social distancing in preventing the spread of the disease. Th is when
hospitals run out of effective PPE. Ts is the initiation time of social distancing.
The proportion of infections due to hospital transmission varies by community.
This proportion is likely to be much smaller in countries with efficient and properly
staffed healthcare systems than in countries where that is not the case, and the hospital or healthcare facilities could be the main hub of transmission. The effectiveness
of PPE, Eh , may vary with the quality of PPE as well as with proper or repeated use.
The effectiveness of social distancing, Es , is likely to vary dramatically between and
within communities based on how seriously the local population follows recommended
or mandated mitigation strategies. The values of Eh and Es were varied.
Figures 9 and 10 give examples of the infection parameter β1 (t), β2 (t), and β
when social distancing starts on day 45 and 105 (Ts = 45, 105), respectively, and
hospitals run out of PPE on day 100 (Th = 100). In this example, the weighted
proportion of the infection rate parameter that is due to the infections within the
hospital, H, is 15%. In Figure 9 initially β is large since there is no social distancing,
and then decreases, once social distancing starts. After β drops, due to the start of
social distancing, it rises again after the hospitals run out of PPE.
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Figure 9 : Social distancing begins at 45 days with modest effectiveness level and
PPE are lost at 100 days.

3.3

Results
To examine the effects of these intervention strategies, the simulations are divided

into three categories of effectiveness of social distancing: high (75%, Es = 0.25),
moderate (60%, Es = 0.4) and modest (40%, Es = 0.6). Social distancing is simulated
to be initiated at different points in time, Ts , after 45, 60, 75, 90 and 105 days of
the initial outbreak. These initiation times are chosen based on the peak number of
infectious individual occurred around 100 days. I assume the effectiveness of PPE
was 80% (Eh = 0.2). To explore the loss of PPE, I consider the cases where there is
an early loss of PPE at 50 days (Th = 50), and a loss near the peak of the number
of infectious individuals at 100 days (Th = 100). It is assumed that once PPE run
out, supplies are not replenished to any significant degree within the time frame of
the simulations. I also assume for convenience that βs = βh .
The initial conditions are S(0) = 4, 500, 000, I(0) = 2, R(0) = 0 to simulate two
cases being introduced into a small country in an outbreak situation. To solve the
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Figure 10 : Social distancing begins at 105 days with modest effectiveness level and
PPE are lost at 100 days.

system of ODEs, the equations were discretized in Microsoft Excel with time steps
of one day and Forward Euler’s Method was applied. The system of ODEs was also
solved in Matlab using ode15s. The simulations are run for 530 days to capture
the dynamics over the course of a year and a half.
Parameters are chosen to exhibit a peak in the infectious class occurring around
100 days without using any intervention strategies. I also assume that individuals
would be infectious for two weeks, and that infections occur between close proximity
between individuals. It is possible that a disease like COVID-19 may be transmitted
through contact with surfaces, though I assume that social distancing and the use
of proper PPE will dramatically reduce the spread through close proximal vicinity
including transfer through surfaces.
The spread of COVID-19 is complex in many respects. Many individuals are
asymptomatic [Whitehead and Feibel, 2020]. Spread can occur between individuals
in close proximity through the air, or through contact to surfaces where the virus can
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remain over time [WHO, 2020]. Due to many factors including the inability to conduct widespread testing, it is difficult to estimate infection rates. Additionally, rates
found in the literature vary over a wide range of values [Mandal et al., 2020, Zhang
et al., 2020, Roda et al., 2020, Cherniha et al., 2020]. Roda et al. [2020] specifically
mentioned that modeling parameters and results vary because of the uncertainty of
when the outbreak began, the complexities in defining who is infected with COVID19, and the wide range in the case-infection ratio [Roda et al., 2020]. In retrospect,
patients did not contract COVID-19 from healthcare facilities at high rates during
the initial outbreak of COVID-19 [Pryor et al., 2022]. Due to this, I consider a future
virulent strain of COVID-19.
3.3.1

Highly effective social distancing

Individuals need to obtain food and other goods, and at times medical care, which
makes social distancing impossible to achieve at extremely high percentages. In this
situation I assume highly effective social distancing reduces the infection parameter
by 75%. Figure 11 shows that postponing social distancing results in a dramatic
increase in the peak number of infections. Starting social distancing before day 75
results in a peak of approximately 225,000 infections, whereas after 75 days, peaks
of 1,000,000 infections or more occur. Delays in peaks allow for healthcare agencies
both time to prepare and with lower peaks the ability to better handle the patient
load.
Comparing β in Figure 9 and 10, it is clear what the effect of a delayed social
distancing from initiating on day 45 in the former and on day 105 in the latter has on
the transmission rate. The former situation has a lower overall β between day 45 and
105. This decrease in β during this time results in the delay in the peak infections
seen in Figure 11. In general initiating social distancing 15 days earlier results in a
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delay in the peak by almost 100 days, unless social distancing starts near 100 days in
which the peak occurs early.
Similar results are seen in Figure 12 where the overall percentage of people who
become infected rises well above 50% when social distancing starts after day 75. This
quickly becomes over 90% of the population having been infected in most cases where
social distancing is started after 90 days. Also seen in Figure 12 is the importance of
hospital protocols and PPEs where there is high hospital transmission. In the case
with low transmission and early social distancing, as seen by the red and blue curves
in Figure 12, the epidemic can be controlled to very low levels when social distancing
begins before 70 days. Starting social distancing later, such at 100 days, abates the
effect of hospital transmission since eventually each situation eventually reaches the
same effective β.
Figure 12 shows the effects of losing PPE. For low hospital transmission the
percent eventually infected drops 3% to 10% for a given day of initiation of social
distancing. In the high hospital transmission case the percent can drop nearly 20%
in some instances. However, when initiation starts early or very late there is nearly
no difference between the early loss of PPE on day 50, or when PPE are lost near the
peak of the infection on day 100.
3.3.2

Moderately effective social distancing

In the case with moderately effective social distancing, with a reduction of 60%
in the infection parameter (Es = 0.4), I see in some cases more than twice the size in
infection peaks than in the highly effective case, see Figure 13. This decrease in the
effectiveness results in the peaks with early social distancing range from 550,000 to
600,000 individuals, whereas the with late social distancing the peaks are again over
1,000,000. Overall this is a significant rise in the peak number of cases with this drop
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Figure 11 : The social distancing effectiveness is 75%, hospital transmission is 15%
and the hospital runs out of PPEs at 100 days.
Percent infected with high social distancing effectiveness
1.0

Low hospital
transmission with loss
of PPEs on day 50

0.8
0.7
0.6

Low hospital
transmission with loss
of PPEs on day 100

0.5
0.4

High hospital
transmission with loss
of PPEs on day 50

0.3
0.2

130

120

125

115

105

110

95

100

85

90

80

70

75

60

65

50

55

0.1
45

Percentage of population infected

0.9

High hospital
transmission with loss
of PPEs on day 100

Day when social distancing begins

Figure 12 : The percentage of the total population infected when social distancing
has a high effectiveness level.
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in effectiveness.
There are still delays in the peak with early initiation of social distancing, though
the delays are noticeably shorter. In the highly effective case the peaks occurred
around 340, 250, and 150 days for social distancing initiation occurring on day 45,
60 and 75, respectively. In the moderately effective scenario the peaks occur approximately on days 200, 170 and 140. Overall these peaks are delayed by approximately
a month for implementing 15 days earlier. This is around a third of the delay in the
highly effective case.
In Figure 14, around day 85, there is an increase in the percentage of the population infected eventually by the virus. However in this case, due to the effectiveness of
social distancing, the benefits to the overall percentage of infected are reduced where
a majority of the population will eventually become infected. The effect of low and
high hospital transmission are relatively small.
The effect of losing PPE is evident in Figure 14 where under low hospital transmission a reduction of 3% to 5% is typical depending on the day of initiation of social
distancing. In the case of high hospital transmission the percent reduction may range
as large as 13%, though again there is little effect whether initiation occurs early or
late.
Modest effective social distancing
For modest effective social distancing, 40% effective (Es = 0.6), the overall effect
are unsurprisingly relatively small. In Figure 15 the number of infections at the peak
are at or above 1,000,000 individuals. It is interesting to observe that there is a small
increase in the peak number of infections with an earlier delay in initiation of social
distancing. The cause of the increase in the size of the peak is due to the higher
infection rate that occurs after day 100, and the fact that on day 100 there is a larger
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Figure 13 : The social distancing effectiveness is 60%, hospital transmission is 15%
and the hospital runs out of PPEs at 100 days.
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Figure 14 : The percentage of the total population infected when social distancing
is moderately effective.
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susceptible population for the situations with earlier initiation, see Figure 15.
The delay in peak infectious individuals exhibited here is on the order of about
10 days for each 15 day increment of earlier initiation of social distancing. This delay
can be important in order to prepare, though the with large scale of the peaks of
infectious individuals the benefits are small compared to the cases of moderate and
high effectiveness.
In Figure 16 nearly the entire population acquires the infection. The effect of
high and low hospital transmission and when the low of PPE occur is relatively small
when compared to the entire population, though the trends are similar to the other
cases. There is a dip in the percentage of infected with the delay in loss of PPE on day
100, this is again due to the higher infection rate on a large susceptible population.
3.3.3

Impact of terminating social distancing

Finally, I examine the situation where social distancing is terminated after being
initiated. In particular, I consider the case where social distancing starts on day
45 and then is terminated on days 150, 200, 250, and 300. The results are seen in
Figure 17.
In each case of termination, a relatively large peak soon follows the termination.
Without termination the peak is a little over 200,000, though the peak grows to over
1.5 million with early termination after 150 days, and to near 700,000 for the late
termination on day 300. Each additional delay of 50 days does have noticeable drop
in the peak as well as a delay in the timing of the peak.
Figure 18 shows that the earlier that social distancing is terminated, the higher
the percentage of the population is infected when social distancing begins at day
45. There are modest differences in the low and high hospital transmission cases.
This does show that ending social distancing before day 300 results in about 90% of
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Figure 15 : The social distancing effectiveness is 40%, hospital transmission is 15%
and the hospital runs out of PPEs at 100 days.
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Figure 16 : The percentage of the population when social distancing has a modest
effectiveness level.
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Figure 17 : The social distancing effectiveness is 60%, hospital transmission is 15%
and the hospital does not run out of PPEs.

the population acquiring the virus, whereas waiting an additional 150 days results in
about 55% of the population getting infected.
3.4

Conclusions
I developed an SIR model with a time-dependent infection parameter that fo-

cuses on the intervention strategies, social distancing and PPE use within hospitals.
My simulations examine a regional population of 4.5 million. Due to change from initiation and termination of social distancing as well as hospitals running out of PPE,
there is dramatic variation in when the peak number of infectious individuals occur
and the size of this peak.
My model is unique because it analyzes the interaction between starting one
infection prevention program and the loss of another. The example that I chose to
model is beginning social distancing and losing adequate PPE supplies in an outbreak
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Figure 18 : This represents the percent of the population eventually infected under
moderately effective social distancing beginning on day 45 and being terminated.
PPEs are assumed to be plentiful.
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of a virulent strain of COVID-19. The model uses average values for nationwide
estimates. I also do not include other factors such as contract tracing and vaccination.
It is clear of the importance of healthcare facilities having sufficient equipment
to reduce the transmission of the disease within the facilities. However, it is also
important that the effectiveness of social distancing is critical in reducing the number
of infections. Public education of social distancing is vital to save lives and to not
burden the health system within each community.
3.5

Discussion
This research example considers a future strain of COVID-19. At the beginning

of the COVID-19 pandemic in 2019, many parameters related to transmission of
the virus were unknown since historical data related to COVID-19 did not exist
[Petropoulos and Makridakis, 2020]. Also, at the time of the research, I made educated
inferences that disease transmission within the country due to hospitalizations may
be 5%, 10% or 15% in the most severe situations. As I know now, hospital-acquired
COVID-19 accounts for about 0.10% of total COVID-19 cases [Pryor et al., 2020].
Instead of applying the model to a country divided by hospitals and the rest of the
community, hospitals could be replaced by a congregate setting where transmission
is high. The initiation and termination of social distancing may still be governed
by the region, but other settings may set their own regulations by extending social
distancing. The implementation of social distancing may also be delayed if facilities
have to rearrange their space and residents, if possible. The effectiveness of social
distancing in the community would not be different than with the hospital example.
However, social distancing can be challenging in congregate settings by limitations of
the physical space.
PPE in nursing homes, jails, homeless shelters and schools would include face
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masks, face shields, gloves and perhaps disinfectants. The timing of the loss of PPE
for staff and residents would still impact the transmission of a disease or infection
through the space, but it would also impact the willingness of staff to show up for
work and/or perform their job at high quality due to safety concerns. In the hospital
setting, the effectiveness of PPE would be mostly driven by the availability of new
supplies since healthcare workers are trained on proper use of PPE. In the congregate
settings, the effectiveness would be mostly determined by the education around PPE
use and by the enforcement of correct use.
Overall, I found that the infection prevention program on the larger subset of
the country has the largest impact on the number of cases of the disease or infection.
There is a large variation in simulation results when the effectiveness and initiation of
the community infection prevention program varies and when the smaller subset loses
an infection prevention program. It is clear of the importance of the smaller subset
having the infection prevention program in place. However, it is also important that
the effectiveness of the community infection prevention program is critical in reducing
the number of infections. An ineffective community program has little effect on the
spread of the disease within the population.
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CHAPTER 4

CLOSTRIDIOIDES DIFFICILE AND ACTIVE DETECTION AND
ISOLATION

4.1

Introduction
Clostridioides difficile (C. diff ) is an anaerobic bacterium that produces spores

and toxins which lead to diarrhea and colitis. Many healthy people live with C. diff
bacteria in their gut as a part of their natural microbiome. However, when the gut is
disturbed, the C. diff bacteria can produce harmful toxins and cause a Clostridioides
difficile infection (CDI). Symptoms of CDI include severe watery diarrhea, fever,
stomach tenderness, loss of appetite and nausea [Centers for Disease Control and
Prevention, 2021]. CDIs are one of the most common healthcare-associated infections
in the United States [Lee et al., 2021]. The CDC report that there are nearly half
a million infections in the United States per year [Centers for Disease Control and
Prevention, 2021]. One report from 2021 estimates that C. diff infections nearly
quadruple hospitalization costs [Spanos, 2021]. It is also estimated that the cost of
treating CDI is $1.5 billion annually in the United States [Zimlichman et al., 2013].
Cases of CDI can be classified upon their origin: community-acquired or hospitalacquired (hospital-onset). If a patient develops symptoms of CDI within 48 hours of
admission and their last hospital discharge was at least 12 weeks ago, then their case
is classified as being community-acquired CDI. However, if a patient has been in the
hospital for more than 48 hours, then the CDI case is considered to be hospitalacquired [Ofori et al., 2018]. A patient may have acquired CDI from the community
through outpatient healthcare institutions, receiving antibiotics through the outpa43

tient healthcare institution or ingesting contaminated food or water [Ofori et al.,
2018].
Immune-compromised individuals, elderly people and patients prescribed antibiotics are more susceptible to getting CDI than the general population [Lee et al., 2021].
Immune-compromised individuals lack the ability to fight off harmful bacteria, such
as toxic C. diff spores. Elderly people are more susceptible to CDI due to frequent
healthcare visits and physiological changes to their gut [Jump, 2013]. Antibiotics
alter the patient’s microbiome, which can trigger otherwise unproblematic C. diff to
produce toxins. In particular, patients in the Bone Marrow Transplant (BMT) unit
are prone to CDI since they are immune-compromised and are prescribed antibiotics
during their treatment [Barker et al., 2018].
C. diff is transmitted when asymptomatically colonized, which I will refer to as
just colonized, and infectious patients shed C. diff spores into the environment and
the spores enter a susceptible patient’s body through the mouth [Mayo Clinic Staff,
2022, Gilboa et al., 2020]. If the patient has three or more loose stools within 24
hours, the patient is tested for toxigenic C. diff to confirm that the patient has CDI
and not another diarrhea-causing condition [Lee et al., 2021]. When the patient is
symptomatic and tested, they are placed under contact precautions. Contact precautions include hand washing with soap and water, wearing gloves and gowns, requiring
patients to stay in an isolated room, and sanitizing the room and equipment with
sporicidal disinfectants [Widmer et al., 2017, Doll et al., 2019].
Instead of only testing patients with symptoms, one can implement active detection and isolation (ADI) where patients are initially tested before entering the hospital
to determine whether they are colonized by C. diff [Thompson, 2018]. When a patient tests positive for C. diff bacteria upon admission, that patient is placed under
contact precautions and is immediately isolated for the remainder of their stay at the
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hospital [Cho et al., 2018].
ADI is not always implemented due to costs and being more resource-intensive
than traditional techniques of testing a patient only when they are symptomatic
[Madden et al., 2018, Weinstein et al., 2007]. Examples of the additional resources
needed for ADI are tests, rooms for isolating patients, healthcare workers to administer the test and protective equipment for healthcare workers. Resistance towards
not implementing ADI also includes feedback from patients about increased isolation,
depression, anxiety, prolonging the patient’s length of stay, and increased wait time
in emergency departments [Weinstein et al., 2007].
Overall though, ADI has shown to reduce the incidence of CDI [Weinstein et al.,
2007, Longtin et al., 2016, Lanzas and Dubberke, 2014, Cho et al., 2018, Barker et al.,
2018]. Particularly vulnerable wards in the hospital, such as the BMT Unit, could
benefit from ADI [Barker et al., 2018]. The goal of my research is to use mathematical
modeling to describe how ADI decreases CDIs and to quantify the costs associated
with ADI compared to testing patients when they show symptoms of CDI in the BMT
Unit.
4.2

Mathematical Model
Because patients acquire C. diff indirectly by ingesting C. diff spores from the

environment, the mathematical modeling technique used for implementing ADI in the
BMT Unit must also incorporate patient interactions with a contaminated environment. Due to the small number of patients in the BMT unit of the hospital, I utilized
an agent-based model (ABM) to simulate the interactions between the patients and
the environment. ABM is a simulation technique incorporating agents and an environment. The agents are autonomous and they can interact with other agents and/or
the environment. In my example, the agents only interact with the environment. The
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agents’ actions in the simulations are governed by rules.
I use an ABM to model patients staying the BMT unit to study the transmission
of C. diff within the unit. In the model, the agents are patients that exhibit independent behavior from other agents. The environment is the BMT unit and healthcare
workers. The environment’s level of contamination is determined by the spores shed
by colonized and infectious patients. When a patient is discharged, I assume that
the patient’s room is disinfected and another patient is admitted into the room. So,
the level of C. diff contamination within the environment decreases when a patient
is discharged.
Although the patients do not directly interact with one another, the indirect patient contributions to the contamination of the environment causes C. diff to spread.
Patients in the BMT unit are at high risk for CDI because of long hospitalizations,
high antibiotic use and because chemotherapy negatively impacts a patient’s intestinal
health [Barker et al., 2018].
I implement two agent-based models, ADI-model and non-ADI model, to measure
the outcomes of implementing ADI on the transmission of C. diff. The two models
consider the practice of testing only symptomatic patients, non-ADI model, depicted
by Figure 19, and the process of ADI of patients, ADI-model, depicted by Figure 20.
The ABM has two main components: the environment and the agents. First,
the environment, P (t), estimates the amount of contamination in the environment
and Ω(t) is the proportion of environment that is contaminated with C. diff spores.
P (t) is defined as:
P (t + 1) = max(0, 0.4P (t) +

X

αi Ti (t)),

where i ∈ {CA , CH , CN , CS , IN , IS , R, D}, αi ∈ {−1, 0, 1, 2}, and Ti is the number of
spores shed by class i.
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Figure 19 : Model diagram for non-ADI model with patient states susceptible, S, susceptible on antibiotics, SA , asymptomatic colonization by environment, CH , asymptomatic colonization by antibiotics, CA , admitted with asymptomatic colonization,
CN , infectious, not-screened yet, IN , infectious, screened, IS , and recovered, R. The
arrows indicate a probability of transitioning to the next class.

The contribution of patients shedding spores is quantified by α∗ where ∗ denotes
the particular class, or state, of the patient. The maximum of zero and the summation
was taken to maintain a non-negative level of C. diff spores in the environment. A
positive α∗ value indicated that the class added spores to the environment and a
negative value removed spores from the environment. Spores are eliminated when a
patient is discharged.
Ω(t) utilizes the total contribution of infectious spores by colonized and infected
patients and is scaled by η and ψ. η influences the threshold point where the environment is at 50% contamination. ψ determines how quickly the environment becomes
toxic to patients. Ω(t) is defined as:
Ω(t + 1) =

ψP (t)
.
η + ψP (t)

The second component of my ABM is the set of patients in the BMT Unit.
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Figure 20 : Model diagram for ADI-model when ADI is implemented. The differences
between non-ADI model and ADI-model are highlighted in gold.

Patients can be in one of eight different compartments on any given day. As seen in
Figure 19, for non-ADI model, patients can either be admitted into S, if they are not
colonized, or CN , if they are. I assume that the general population is colonized at a
rate of (1 − b). From S, a patient can be prescribed antibiotics and move into the SA
class, or they can become colonized from exposure with a contaminated environment
(transmitted via surfaces and healthcare workers) and transition into the CH class.
Every patient can be discharged from class κ, κ ∈ {S, SA , CH , CA , CN , R}, at a rate of
δκ , unless they are infectious. Patients are transitioned from susceptible to colonized
at the rate σz Ω(t), z ∈ {S, SA }.
From SA , if a patient becomes colonized, the patient moves into CA . Any colonized patient, CA , CH , CN , can develop CDI and transition into IN . Patients in IN
have not yet been placed under contact precautions. Once a patient is in IN , they
can only transition into the IS class. While a patient is being treated for CDI in IS ,
they stay in IS with additional contact precautions. When they recover, they move
to R. Once a patient is in R, they remain there until they are discharged.
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Incorporating ADI alters one patient compartment and one transition between
compartments in the model. With ADI implemented, before patients are admitted,
they are tested for colonization of C. diff bacteria and are immediately placed under
contact precautions in CS if they test positive. Otherwise, if they are not colonized,
they are placed in S, seen in Figure 20.
The goal of the research is to determine how ADI reduces cases of CDI, and to
track hospital-acquired and community-acquired infections. Patients that transition
from either CH to IN or CA to IN count as hospital-acquired CDIs. The number
of community-acquired cases of CDI is calculated by counting the number of new
patients entering IN from CN in non-ADI model. In ADI-model, the number of
community-acquired cases was calculated by adding all of the patients who transition
from CS to IS .
The other research goal is to quantify the cost of implementing ADI and compare
it to the cost of testing patients only when they are symptomatic. In non-ADI model,
any time a patient entered IN , a test was taken and accounted for. In ADI-model,
all admitted patients were tested in addition to any patient who entered IN from
{CH , CA } or IS from CS . Other costs to consider are the costs of contact precautions
and disinfecting patient rooms. Contact precautions were implemented for patients in
IS in non-ADI model and for patients in both CS and IS in ADI-model. In addition to
disinfecting rooms occupied by patients in IS , ADI-model assumes full environmental
cleaning of rooms occupied by patients in CS as well.
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4.3

Results

4.3.1

Simulation Results

In order to quantify the impact of implementing ADI in the BMT unit, I assume
the unit to always be at full capacity of 21 patients. Patients have an average stay
of six weeks. Simulations were run in Matlab R2021a for one year before making
calculations to avoid transients. Results are based on the averages of 100 - 10 year
simulations.
The parameters used in the simulations are shown in Table 4. Huang et al.
[2016] estimated that about 20% of patients are already colonized with C. diff upon
admission, so the remaining 80%, b, are assumed to be admitted into S. In the
BMT Unit, patients are prescribed antibiotics due to being immune-compromised
[BeTheMatch.org, 2022]. These patients typically receive antibiotics within the first
six days of their hospital stay, so the daily probability of being prescribed antibiotics
is λ = 1/6. If a patient develops CDI, a 10-day course of antibiotics is typically used
to treat the infection, so γ = 1/10 is the daily rate of recovery from CDI [Leffler and
Lamont, 2015].
The remaining parameters are estimated based upon CDI data from the BMT
unit within VCU Medical Center from February 2014 until December 2019 (77 months)
before ADI. The data are visualized in Figure 21. The data has a yearly average of
25.29 infections and a yearly standard deviation of 4.19 infections.
The averages taken over 100 simulations with my estimated parameters in nonADI model agree with the real data as confirmed by a two-sample t-test under 99%
confidence. After the simulations were run, a random sample of 77 months was taken
by using the datasample method in Matlab R2021a. An F-test was conducted at
99% confidence to test if the variances between the simulated data and the real data
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were the same. The null hypothesis that the variances were the same was not rejected,
so a two-sample t-test could be conducted. A t-test looks at overall variability in the
simulated data and compares it to the overall variability in the real data.

Figure 21 : Monthly C. diff data from VCU Medical Center BMT unit from February
2014 - December 2019.

When ADI is implemented, there is an estimated 23% decrease in the total number of infections between non-ADI model and ADI-model in Table 5. The number of
community-acquired infections does not change because 20% of patients are assumed
to be colonized with C. diff from the community in both models. This results in
an overall reduction in 6.42 CDIs per year, which is a 84.38% reduction in hospitalacquired cases. The reduction in cases of CDI from ADI-model compared to the data
are statistically significantly different under 99% confidence in a two-sample t-test.
Unfortunately, community-acquired infections are inevitable since about 20% of
the population is already colonized with C. diff [Hung et al., 2015]. However, as
expected, implementing ADI reduces the number of hospital-acquired infections due
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Parameter
symbol
αIN
b
η
ψ
γ
λ
σS

σSA
θCA
θCH

θCN

θCS

Parameter description
Contribution of spores by
patients in the IN state
Proportion of patients admitted
as susceptible
Environment coefficient
Environment impact scalar
Rate of recovery
Rate of antibiotic prescription
Rate of susceptible patients
becoming colonized with C. diff
from the environment
Rate of susceptible patients on
antibiotics becoming colonized
with C. diff
Rate of colonized patients on
antibiotics becoming symptomatic
Rate of colonized patients from
the environment becoming
symptomatic
Rate of admitted
colonized patients becoming
symptomatic in non-ADI model
Rate of admitted
colonized patients becoming
symptomatic in ADI-model

Parameter
value

Source

2

Estimated

0.800

[Hung et al., 2015]

1000
6
0.100
0.167

Estimated
Estimated

0.010

Estimated

0.050

Estimated

0.017

Estimated

0.100

Estimated

0.017

Estimated

0.017

Estimated

[Leffler and Lamont, 2015]
[BeTheMatch.org, 2022]

Table 4 : Parameter values used in the simulations. Estimated parameters come from
data from the BMT Unit at VCU Medical Center from February 2014 - December
2019.

to contact precautions placed on colonized patients and the contribution of spores
to the environment is reduced. When the environment is less contaminated, patients
are less likely to acquire C. diff.
For all cases of CDI, according to research conducted by Barker et al. [2020],
the excess hospital cost attributable to a new case of CDI is $13,779.31. Table 5
shows that the average of 25.29 infections per year results in $348,478.75 spent on
treating patients with CDI. Non-ADI model had an average of 25.60 infections per
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Percent of infections
that are community-acquired
Percent of infections
that are hospital-acquired
Average number of
community-acquired
infections per year
Average number of
hospital-acquired
infections per year
Average number of
infections per year
Number of tests per year
Number of additional patients
placed under contact precautions per year
Number of additional rooms
to disinfect upon discharge
Cost of infections per year
Cost of tests per year
Cost of additional contact
precautions per year
Cost of additional terminal
cleaning per year
Total cost per year

Data

non-ADI model

ADI-model

69.00%

70.31%

93.84%

31.00%

29.69%

6.16%

17.25

17.98

17.99

7.75

7.62

1.19

25.29

25.60

19.18

–

25.60

195.46

–

–

17

–

–

17

$348,478.75
–

$352,750.34
$200.19

$264,287.17
$1,329.40

–

–

$1,845.35

–

–

$9,616.73

–

$352,950.53

$277,277.75

Table 5 : Results from ABM simulations over ten years with 100 simulations.

year which results in $352,750.34 spent on treating patients with CDI. When the
number of infections are reduced to an average of 19.18 in ADI-model, the total cost
for treating patients with CDI decreases to $264,287.17. This results in $88,463.17
saved by preventing CDI with ADI.
ADI reduces CDIs, but does require more resources than not implementing ADI.
Additional costs associated with ADI include the cost of testing a patient, $7.82,
implementing contact precautions, $108.55, and thoroughly disinfecting any room
that contained a colonized or infectious patient $565.69 [Barker et al., 2020].
As seen in Table 5, increasing the number of tests from 25.60 without ADI to
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195.46 results in about 170 additional tests. One-hundred seventy additional tests
(170 * $7.82) costs $1,329.40. Implementing contact precautions on an additional 17
patients ($108.55 * 17), those patients who were colonized upon admission in ADImodel, costs $1,845.35. Then, disinfecting the 17 additional rooms ($565.69 * 17) of
the CS patients costs $9,616.73.
Although ADI requires these additional costs, these costs do not outweigh the
costs of treating cases of CDI. Seven preventable cases of CDI by not implementing
ADI costs $96,455.17 ($13,779.31 * 7) based on costs from Barker et al. [2020]. The
costs of treating CDI and the costs of ADI resources are combined at the bottom of
Table 5. Comparing ADI-model to non-ADI model, I see that ADI can save about
$83,663.69 per year.
4.3.2

Parameter Sensitivity Analysis

I explore implementing ADI by adjusting the values of the parameters to determine how the results are sensitive to each of the parameters. This allows one to
understand which parameters within the model are most significant in influencing the
number of yearly infections. Here, each parameter was doubled and cut in half. The
outcomes of the number of yearly community-acquired CDIs, hospital-acquired CDIs,
average number of yearly CDIs and number of tests used per year were calculated
after adjusting the parameters. These results are shown in Table 6 for non-ADI model
and in Table 7 for ADI-model.
The parameters chosen are those that could potentially be monitored or modified with medical and scientific advancements. For instance, σS and σSA could be
monitored if it was known exactly how and when a patient became colonized with additional testing. ψ could be altered by the effectiveness of disinfecting patient rooms.
Being able to predict how quickly a patient who is colonized upon admission became
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non-ADI model
σS
= 0.01
= 0.02
= 0.005
σSA
= 0.05
= 0.1
= 0.025
ψ
=6
= 12
=3
θCN
= 0.02
= 0.04
= 0.01
γ
= 0.1
= 0.2
= 0.05

# of Comm.
Infs Per Year

# of Hosp.
Infs Per Year

Mean # of
Yearly Infs

# Tests
Per Year

17.98
17.95
17.98

7.62
7.90
7.46

25.60
25.85
25.44

25.60
25.85
25.44

17.98
17.80
18.16

7.62
16.36
3.76

25.60
34.15
21.92

25.60
34.15
21.92

17.98
17.81
17.75

7.62
15.85
3.61

25.60
33.66
21.36

25.60
33.66
21.36

17.98
26.75
10.55

7.62
7.64
7.62

25.60
34.38
18.17

25.60
34.38
18.17

17.98
18.06
17.59

7.62
7.47
8.08

25.60
25.53
25.67

25.60
25.53
25.67

Table 6 : Parameter sensitivity results for non-ADI model, when ADI is not imple-

mented.
symptomatic, θCN and θCS , would influence the urgency of preventative practices to
be used on these patients. The strength of the antibiotics used to treat CDI would
impact how quickly a patient recovered, which is γ in both models.
By manipulating the parameters, I found that both models are sensitive to σSA ,
the rate at which susceptible patients on antibiotics become colonized, but neither
model is sensitive to σS . In Table 6, doubling σSA more than doubles the number
of yearly hospital-acquired infections per year and cutting σSA in half reduces yearly
hospital-acquired cases by more than 50%. The results for the parameter sensitivity
analysis for ADI-model in Table 7 show a similar reaction towards hospital-acquired
CDIs to altering σSA .
Because all BMT patients receive antibiotics as a part of their treatment, increas55

ADI-model
σS
= 0.01
= 0.02
= 0.005
σSA
= 0.05
= 0.1
= 0.025
ψ
=6
= 12
=3
θCS
= 0.02
= 0.04
= 0.01
γ
= 0.1
= 0.2
= 0.05

# of Comm.
Infs Per Year

# of Hosp.
Infs Per Year

Mean # of
Yearly Infs

# Tests
Per Year

17.99
18.00
17.79

1.19
1.16
1.17

19.18
19.19
18.96

195.46
195.46
195.35

17.99
17.84
17.51

1.19
2.43
0.61

19.18
20.26
18.11

195.46
196.50
194.57

17.99
18.07
18.06

1.19
1.18
1.12

19.18
19.25
19.17

195.46
195.57
195.51

17.99
26.62
10.61

1.19
1.17
1.20

19.18
27.79
11.81

195.46
204.01
188.41

17.99
17.99
17.58

1.19
1.18
1.23

19.18
19.17
18.81

195.46
196.20
192.75

Table 7 : Parameter sensitivity analysis for ADI-model, when ADI is implemented.

ing the rate that those patients become colonized and ultimately symptomatic would
increase the number of yearly infections. Similarly, reducing the rate of colonization
would allow patients to avoid getting C. diff before they are discharged. The models
are not reactive to σS because patients rarely transition from S to CH .
In Table 6, I see that non-ADI model is sensitive to ψ. When ψ is doubled,
the number of hospital-acquired infections per year more than doubles. When ψ
is reduced by half, the number of hospital-acquired infections is reduced by about
53%. Because the environment is less controlled in non-ADI model, since colonized
patients are unknown and therefore shed spores into the environment. This impacts
the environment and increases the rate of susceptible patients becoming colonized
that could increase the number of hospital-acquired C. diff cases. ADI-model is less
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effected by the environment because there are fewer unknown colonized patients and
therefore fewer spores contaminating the environment.
In Table 7, I see that ADI-model is not sensitive to ψ since increased awareness
of who is colonized with C. diff reduces the amount of spores that contaminate the
environment. ψ scales the effect of the environment, but with only 6% of patients
getting CDI due to the contaminated environment in ADI-model, doubling or halving
the value does not impact many patients.
Both models are also sensitive to θCN and θCS , the rates of patients who are
colonized upon admission become symptomatic. Tables 6 and 7 both show that yearly
community-acquired cases of CDI are doubled when θCN and θCS are respectively
doubled. When θCN and θCS are reduced by half, the number of community-acquired
infections are reduced by about 39%.
θCN and θCS are significant parameters because they represent the movement of
patients into the symptomatic infected class. Decreasing the rate of this transition
would allow patients to stay within the colonized class until they are discharged. ADI
identifies colonized patients initially and institutes preventative measures to decrease
the spores from spreading into the environment. Otherwise colonized patients that are
not immediately isolated can contribute more spores to the environment consequently
causing more infections to susceptible patients.
Both models are not sensitive to γ since γ affects recovery of CDI, which does not
play a large role in transmission of C. diff. While γ affects the amount of spores contributed into the environment by patients waiting to recover from CDI, the additional
days spent in IS are not enough days for a patient to make a significant contribution
of spores into the environment to impact yearly infections.
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4.4

Discussion
Utilizing an ABM with eight patient states allows me to quantify the impact of

implementing ADI in the BMT unit on the number of cases of CDI and to generate
a data set statistically similar to the data provided by VCU Medical Center. The
data have a yearly average of 25.29 infections and a yearly standard deviation of 4.19
infections. Upon implementing ADI, I found a 25% reduction, on average, in total
cases of CDI per year. Additionally, there is an 84.38% decrease in hospital-acquired
cases alone.
Modeling patients in the BMT unit is challenging due to the varying underlying
conditions that the patients are in, the variable, long length of stays and the high rate
of antibiotic prescription [Barker et al., 2018]. Cases of CDI may occur in outbreaks
due to a contaminated environment or may be isolated cases from those that are
colonized.
ADI reduces hospital-acquired cases of CDI due to the reduction of spore shedding by infectious patients through the implementation of contact precautions on
all known cases of colonization and active infection. However, while ADI identifies
community-acquired colonizations, it cannot prevent community-acquired colonizations from being admitted into the BMT unit.
My results are in agreement with other studies of implementing ADI in the BMT
unit showing that ADI could reduce hospital-acquired cases of CDI. My results showed
a 84.38% decrease in hospital-acquired cases of CDI when ADI was implemented.
Barker et al. [2018] showed an 82.93% reduction, and Lanzas and Dubberke [2014]
showed a 25% reduction in hospital-acquired cases of CDI with ADI. Lanzas and
Dubberke [2014] studied six medicine wards within a hospital with two strains of C.
diff. The data in the study showed that 58% of CDI cases were hospital-acquired.
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After using an ABM to model ADI, the mean number of hospital-acquired CDI cases
were reduced by 25% [Lanzas and Dubberke, 2014]. Because the study was set in less
vulnerable wards within the hospital, it is less likely that the patients would develop
CDI.
Barker et al. [2018] studied the impact of ADI on CDI cases specifically in
the BMT unit at a hospital in Madison, Wisconsin. Pre-intervention and postintervention data show that 10.3% of BMT patients were tested for C. diff upon
admission before screening was implemented and increased to 74.5% upon implementation [Barker et al., 2018]. There was a 82.93% decrease in hospital-acquired cases
of CDI within the study.
The parameter sensitivity analysis provides insight on which parameters are most
important to focus on to prevent or lower the chance of patients getting CDI. Both
models, with and without ADI, are sensitive to σSA , the rate at which susceptible patients on antibiotics become colonized, and θCN and θCS , the rates of patients who are
colonized upon admission become symptomatic. Healthcare providers should monitor patients who are prescribed antibiotics by potentially testing those patients for C.
diff bacteria and toxins. Furthermore, knowing which patients are admitted with C.
diff would allow for proper contact precautions and careful antibiotic prescription to
occur to prevent the asymptomatic colonization from becoming an active and symptomatic infection. It is also important to note that results are not sensitive in terms
of the parameters estimating the effects of the environment under ADI since the colonized patients are better controlled, unlike in the non-ADI situation. This implies
that awareness of which patients are colonized upon admission ultimately reduces the
environment’s impacts on other patients.
The basic structure of my model could allow for more questions about preventing
cases of CDI from occurring by altering different parameters, such as the testing
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accuracy. In this study I did not consider the effect of testing accuracy of CDI. I
assumed that testing of CDI and colonization is 100% accurate. If this was not the
case, then patient transitions would be more complicated as well as the resulting
dynamics.
Overall, the ABM allowed me to track the status of patients in the BMT unit in
order to track patients developing CDI, with and without ADI in place. I were also
able to break down the cases of CDI into hospital-acquired and community-acquired
to quantify the impact of ADI on the reduction of hospital-acquired cases specifically.
Given the high cost of a case of CDI and the relatively low cost of a PCR test, my
study also supports the implementation of ADI from a cost savings perspective.
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CHAPTER 5

CONCLUSIONS AND DISCUSSION

I have presented multiple different mathematical models that simulate the effects of
different intervention strategies in order to limit the cases of hospital-acquired infections. In each of these different models, I quantified the subsequent impact on
yearly cases of HAIs and estimated the resulting costs. This research supports implementing the particular intervention strategies examined within each model where the
cost of implementing the infection prevention programs outweigh the cost of treating
HAIs. Reducing HAIs allows hospitals to decrease the amount of resources and time
necessary for treating each individual patient, which has positive consequences for
healthcare costs and for the patient’s experience during their hospitalization.
A variety of mathematical modeling techniques were used in my research. The
studies that I conducted incorporated a combination of infection prevention techniques. Each problem also presented unique set of assumptions, focused on a specific
set of HAIs, and required me to track and emphasize different components of the
model. Developing mathematical models to quantify the impact of infection prevention programs is challenging because the parameters required for the simulations
have to be estimated. Clinical studies cannot be ethically performed for the research
problems proposed, so precise parameters are not available.
Chapter 2 supports early action of using CHG bathing to prevent HAIs, and encourages healthcare leaders to enforce high levels of CHG bathing compliance hospitalwide. I also saw that immediate full implementation of the standardized central line
bundle kit and CHG bathing resulted in more CLABSIs and CAUTIs prevented and
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more savings than when the implementation of these programs were delayed.
In Chapter 3, I simulated the loss of one infection intervention practice and the
start of another. The results predict how the interplay of the two strategies affects
the community as a whole. I found that the effectiveness of the infection prevention
program used on the entire community has the largest impact on the size and timing
of the peak number of infections during an outbreak.
Finally, in Chapter 4, I modeled the reduction in hospital-acquired cases of CDI
when ADI was implemented on patients in the BMT Unit. While community-acquired
cases were not reduced, they were identified with ADI and therefore the amount of
spores being contributed to the environment was reduced. Because the environment
was less contaminated, hospital-acquired cases of CDI decreased when ADI was implemented. The parameter sensitivity analysis allowed me to identify transitions
between patient states that had the greatest impact on yearly cases of CDI. I found
that the rate of patients on antibiotics becoming colonized with C. diff and patients
who are colonized becoming symptomatic have a significant impact on cases of CDI.
Even with today’s medical advancements, HAIs continue to increase the mortality and morbidity of hospitalizations as antibiotic-resistant organisms become more
prevalent. HAIs are preventable through the implementation of infection prevention
programs. Overall, effective compliance and early initiation of infection prevention
programs can reduce the burden of HAIs on healthcare systems and improve patient
outcomes.
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Appendix A

ABBREVIATIONS

ABM

Agent-based model

ADI

Active Detection and Isolation

BMT

Bone Marrow Transplant

CAUTI

Catheter-associated urinary tract infection

CDC

Centers for Disease Control and Prevention

CDI

Clostridiodes difficile infection

CHG

Chlorhexidine gluconate

CLABSI

Central line-associated bloodstream infection

HAI

Hospital-acquired infection

PPE

Personal protective equipment

VCU

Virginia Commonwealth University
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Appendix B

MATLAB CODE– CHG BATHING ONLY

infectionsTable = ["Uniform discharge rate" "discharge ...
PI" "Daily probability of infection" "CHG Bathing ...
compliance" "Number of yearly infections" "N0 at ...
equi" "N1 at equi" "N2 at equi" "P0 at equi" "P1 at ...
equi" "P2 at equi" "P3 at equi" "PI at equi" "total ...
number of patients"];
betaValues = [0 .10 .20 .30 .40 .50 .60 .70 .80 .90 1.00];
∆ Values = [1/14 1/12 1/10 1/9 1/8 1/7 1/6 1/5 1/4 1/3 1/2];
%28% effectiveness
rValues = [0.000345];
%71% effectiveness
%rValues = [0.000665];
for d=1:length( ∆ Values)
for r=1:length(rValues)
for b=1:length(betaValues)
infections = [];
∆ N0 = ∆ Values(d); %discharge rates
∆ N1 = ∆ N0;
∆ N2 = ∆ N0;
∆ P0 = ∆ N0;
∆ P1 = ∆ N0;
∆ P2 = ∆ N0;
∆ P3 = ∆ N0;
∆ PI = 1/10;
%

%

28% effectiveness
r3 = rValues(r); %infection rates
r2 = (1-.0933333)*rValues(r);
r1 = (1-.1866666)*rValues(r);
r0 = (1-.28)*rValues(r);
r0prime = 0.95*r0;
r1prime = 0.95*r1;
r2prime = 0.95*r2;
71% effectiveness
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%
%
%
%
%
%
%

r3 = rValues(r); %infection rates
r2 = (1-.236666667)*rValues(r);
r1 = (1-.473333333)*rValues(r);
r0 = (1-.71)*rValues(r);
r0prime = 0.95*r0;
r1prime = 0.95*r1;
r2prime = 0.95*r2;
beta0=betaValues(b); %each of the bathing
rates for the iterations are set here
beta1=betaValues(b);
beta2=betaValues(b);
beta3=betaValues(b);

...

t = 365; %number of days the simulation was run
%
%
%
%
%
%
%
%

N0 = 125;
N1 = 50;
N2 = 25;
P0 = 150;
P1 = 150;
P2 = 150;
P3 = 150;
PI=50;
N0 = 0;
N1 = 850;
N2 = 0;
P0 = 0;
P1 = 0;
P2 = 0;
P3 = 0;
PI = 0;

%number of patients in each class

totalPop = N0 + N1 + N2 + P0 + P1 + P2 + P3
+ PI;
% % ----- discharge matrix ----dischargeMatrix = zeros(8,8); %setting up
the discharge matrix
dischargeMatrix(1,1)
dischargeMatrix(1,2)
dischargeMatrix(1,3)
dischargeMatrix(1,4)
dischargeMatrix(1,5)
dischargeMatrix(1,6)
dischargeMatrix(1,7)
dischargeMatrix(1,8)

= 1;
= ∆ N1;
= ∆ N2;
= ∆ P0;
= ∆ P1;
= ∆ P2;
= ∆ P3;
= ∆ PI;

dischargeMatrix(2,2) = 1 76

∆

N1;

...

...

dischargeMatrix(3,3)
dischargeMatrix(4,4)
dischargeMatrix(5,5)
dischargeMatrix(6,6)
dischargeMatrix(7,7)
dischargeMatrix(8,8)

=
=
=
=
=
=

1
1
1
1
1
1

-

N2;
P0;
∆ P1;
∆ P2;
∆ P3;
∆ PI;
∆
∆

% % ----- infection matrix ----infectMatrix = zeros(8,8); %setting up the
infection matrix
infectMatrix(1,1)
infectMatrix(2,2)
infectMatrix(3,3)
infectMatrix(4,4)
infectMatrix(5,5)
infectMatrix(6,6)
infectMatrix(7,7)
infectMatrix(8,8)

=
=
=
=
=
=
=
=

1 1 1 1 1 1 1 1;

infectMatrix(8,1)
infectMatrix(8,2)
infectMatrix(8,3)
infectMatrix(8,4)
infectMatrix(8,5)
infectMatrix(8,6)
infectMatrix(8,7)

=
=
=
=
=
=
=

r0prime;
r1prime;
r2prime;
r0;
r1;
r2;
r3;

...

r0prime;
r1prime;
r2prime;
r0;
r1;
r2;
r3;

% % ----- bathing matrix ----batheMatrix = zeros(8,8); %setting up the
bathing matrix

...

batheMatrix(2,1) = 1 - beta0; %then entered ...
into the matrix
batheMatrix(3,2) = 1 - beta1; %the code is ...
set up this way to accomodate
batheMatrix(7,3) = 1 - beta2; %for when I ...
want the bathing rate to be
batheMatrix(5,4) = 1 - beta0; %a random ...
number from a normal distribution
batheMatrix(6,5) = 1 - beta1;
batheMatrix(7,6) = 1 - beta2;
batheMatrix(7,7) = 1 - beta3;
batheMatrix(8,8) = 1;
batheMatrix(4,1)
batheMatrix(4,2)
batheMatrix(4,3)
batheMatrix(4,4)
batheMatrix(4,5)
batheMatrix(4,6)

=
=
=
=
=
=
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beta0;
beta1;
beta2;
beta0;
beta1;
beta2;

batheMatrix(4,7) = beta3;
% % ----- patient matrix ----patientMatrix = zeros(8,1); %setting up the
patient matrix
patientMatrix(1,1)=N0;
patientMatrix(2,1)=N1;
patientMatrix(3,1)=N2;
patientMatrix(4,1)=P0;
patientMatrix(5,1)=P1;
patientMatrix(6,1)=P2;
patientMatrix(7,1)=P3;
patientMatrix(8,1)=PI;

...

newPatients0 =[];
newPatients1 = [];
newPatients2 = [];
patients0 = [];
patients1 = [];
patients2 = [];
patients3=[];
patientsInfected = [];
application1 = dischargeMatrix*infectMatrix;
application2 = application1*batheMatrix;
for i = 1:465
patientMatrix = application2*patientMatrix;
newPatients0 = ...
[newPatients0;patientMatrix(1,1)];
newPatients1 = ...
[newPatients1;patientMatrix(2,1)];
newPatients2 = [newPatients2; ...
patientMatrix(3,1)];
patients0 = [patients0;patientMatrix(4,1)];
patients1 = [patients1;patientMatrix(5,1)];
patients2 = [patients2;patientMatrix(6,1)];
patients3 = [patients3;patientMatrix(7,1)];
patientsInfected = ...
[patientsInfected;patientMatrix(8,1)];
end
ceil(patientMatrix);
newInfectionsMatrix = [];
for m=1:465 %calculating new infections
newInfections = r0prime*newPatients0(m) ...
+ r1prime*newPatients1(m) + ...
r2prime*newPatients2(m)+ ...
r0*patients0(m) + r1*patients1(m) + ...
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r2*patients2(m) + r3*patients3(m);
newInfectionsMatrix = ...
[newInfectionsMatrix; newInfections];
end
newInfectionsMatrix2 = [];
for j=100:465 %only looking at new ...
infections beyond one hundred days of ...
the simulation
newInfections2 = ...
r0prime*newPatients0(j) + ...
r1prime*newPatients1(j) + ...
r2prime*newPatients2(j)+ ...
r0*patients0(j) + r1*patients1(j) + ...
r2*patients2(j) + r3*patients3(j);
newInfectionsMatrix2 = ...
[newInfectionsMatrix2; newInfections2];
end
sum(newInfectionsMatrix2);
infections = ...
[infections;sum(newInfectionsMatrix2)];
ev = 465;
infectionVector = [ ∆ Values(d) ∆ PI ...
rValues(r) betaValues(b) ...
mean(infections) newPatients0(ev) ...
newPatients1(ev) newPatients2(ev) ...
patients0(ev) patients1(ev) ...
patients2(ev) patients3(ev) ...
patientsInfected(ev) ...
sum(newPatients0(ev)+newPatients1(ev)+newPatients2(ev)
+patients0(ev)+patients1(ev)+ ...
patients2(ev)+patients3(ev)+patientsInfected(ev))];
infectionsTable = [infectionsTable;
infectionVector];
end
end
end
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Appendix C

MATLAB CODE – RESISTORS AND CONSTIPATORS

clear all
betaStar = 1.0;
CL = 1/18; %average LOS for patient with central line: ...
18 days ...
(https://academic.oup.com/intqhc/article/29/1/63/2660332)
∆ Cath = 1/10; %average LOS for patient with catheter:
...
10 days ...
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378875/)
∆ CLinf = 1/24; %average LOS for patient with CLABSI: 24
...
days ...
(https://academic.oup.com/intqhc/article/29/1/63/2660332)
∆ Cathinf = 1/18; %average LOS for patient with CAUTI:
...
18 days ...
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378875/)
∆ Other = 1/5; %average LOS for patient in hospital
...
without device
∆

%getCL = 0.2; ...
%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997807/
%getCath = 0.12; ...
%https://www.ncbi.nlm.nih.gov/pubmed/28392431
getCL = 0.0123203;
getCath = 0.012702;
getCLandCath = getCL*getCath;
eta1 = 0.59;
eta2 = 0.5;
eta3 = 0.55;
kappa1 = 0.3;
kappa2 = 0.3;
%CLABSI has a 56% reduction with CHG bathing
% Need to also include further reduction with
standardized kit
% estimating impact to be an additional 10%
r03 = 0.000405;
80

...

r02 = (1- (eta1 +kappa1)*(1/3))*r03;
r01 = (1- (eta1 + kappa1)*(2/3))*r03;
r00 = (1- (eta1 + kappa1))*r03;
%CAUTI has a 32% reduction with CHG bathing
r13 = 0.03;
r12 = (1- (eta2 /3))*r13;
r11 = (1 - (eta2 *(2/3))) * r13;
r10 = (1 - eta2)* r13;
%I am going to assume a 44% reduction if you have both
% Need to also include further reduction with ...
standardized kit
% estimating further impact to be 10%
r23 = (r03+r13)/3;
r22 = (1 - (eta3+kappa2)/3)*r23;
r21 = (1 - 2*(eta3+kappa2)/3) * r23;
r20 = (1 - (eta3+kappa2))*r23;
r03prime
r02prime
r01prime
r00prime

=
=
=
=

r23;
(1 - (eta3+kappa2)/3)*r03prime;
(1 - 2*(eta3+kappa2)/3)*r03prime;
(1 - (eta3+kappa2))*r03prime;

r13prime
r12prime
r11prime
r10prime

=
=
=
=

r23;
(1 - (eta3+kappa2)/3)*r13prime;
(1 - 2*(eta3+kappa2)/3)*r03prime;
(1 - (eta3+kappa2))*r03prime;

rI0 = r23;
rI1 = r23;

years = 5; %years interested in computing to
daysInYear = 365;
daysInMonth = 30.4;
currentComp = 0.6; %current CHG bathing compliance
desiredComp = 0.9; %desired CHG bathing compliance

monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30 33
36 39 42 45 48 51 54 57 60];

...

%monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30 33
36 39 42 45 48 51 54]; %comment out (1)

...

%monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30 33
36 39 42 45 48]; %comment out (1)-(2)

...

%monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30 33
36 39 42];

...
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%comment out (1)-(3)
%monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30 33
36]; %comment
%out (1)-(4)
%monthIncrementTest = [0 3 6 9 12 15 18 21 24 27 30];
%comment out (1)-(5)
%monthIncrementTest = [0 3 6 9 12 15 18 21 24];
%comment out (1)-(6)

...

...

...

%monthIncrementTest = [0 3 6 9 12 15 18]; %comment out
(1)-(7)
%monthIncrementTest = [0 3 6 9 12]; %comment out (1)-(8)
%monthIncrementTest = [0 3 6]; %comment out (1)-(9)
% monthIncrementTest = [0];
timeStep = ceil(daysInMonth*monthIncrementTest);
inc = (desiredComp - ...
currentComp)/(length(monthIncrementTest)-1);
ss = 300;
t = years*daysInYear + ss ; %total time
%betaChoices = [0 0.225 .45 .675 .90];
beta=[];
betaInc=[currentComp:inc:desiredComp];
for i=1:t
if (i ≥ 1) && (i<timeStep(2))
beta(1,i)=betaInc(1,1);
elseif (i ≥ timeStep(2))&& (i<timeStep(3))
beta(1,i) = betaInc(1,2);
elseif (i ≥ timeStep(3))&& (i<timeStep(4)) %(9)
beta(1,i) = betaInc(1,3);
elseif (i ≥ timeStep(4))&& (i<timeStep(5)) %(9)
beta(1,i) = betaInc(1,4);
elseif (i ≥ timeStep(5))&& (i<timeStep(6)) %(8)
beta(1,i) = betaInc(1,5);
elseif (i ≥ timeStep(6))&& (i<timeStep(7)) %(8)
beta(1,i) = betaInc(1,6);
elseif (i ≥ timeStep(7))&& (i<timeStep(8)) %(7)
beta(1,i) = betaInc(1,7);
elseif (i ≥ timeStep(8)) && (i<timeStep(9) )%(7)
beta(1,i) = betaInc(1,8);
elseif (i ≥ timeStep(9))&& (i<timeStep(10)) %(6)
beta(1,i) = betaInc(1,9);
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...

elseif (i ≥ timeStep(10))&& (i<timeStep(11))
beta(1,i) = betaInc(1,10);
elseif (i ≥ timeStep(11))&& (i<timeStep(12))
beta(1,i) = betaInc(1,11);
elseif (i ≥ timeStep(12))&& (i<timeStep(13))
beta(1,i) = betaInc(1,12);
elseif (i ≥ timeStep(13))&& (i<timeStep(14))
beta(1,i) = betaInc(1,13);
elseif (i ≥ timeStep(14))&& (i<timeStep(15))
beta(1,i) = betaInc(1,14);
elseif (i ≥ timeStep(15))&& (i<timeStep(16))
beta(1,i) = betaInc(1,15);
elseif (i ≥ timeStep(16))&& (i<timeStep(17))
beta(1,i) = betaInc(1,16);
elseif (i ≥ timeStep(17))&& (i<timeStep(18))
beta(1,i) = betaInc(1,17);
elseif (i ≥ timeStep(18))&& (i<timeStep(19))
beta(1,i) = betaInc(1,18);
elseif (i ≥ timeStep(19))&& (i<timeStep(20))
beta(1,i) = betaInc(1,19);
elseif (i ≥ timeStep(20))&& (i<timeStep(21))
beta(1,i) = betaInc(1,20);
else
beta(i) = 0.9;
end
end
% for i=1:t
%
if i ≥ 0 && i<365+ss
%
beta(1,i) = betaChoices(1);
%
elseif i ≥ 365+ss && i<730+ss
%
beta(1,i) = betaChoices(2);
%
elseif i ≥ 730+ss && i< 1095+ss
%
beta(1,i) = betaChoices(3);
%
elseif i ≥ 1095+ss && i< 1460+ss
%
beta(1,i) = betaChoices(4);
%
else
%
beta(1,i) = betaChoices(5);
%
end
% end
plot(beta)
newPatients = [];
circPatients = [];
clPatients0 = [];
clPatients1 = [];
clPatients2 = [];
clPatients3 = [];
cathPatients0 = [];
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%(6)
%(5)
%(5)
%(4)
%(4)
%(3)
%(3)
%(2)
%(2)
%(1)
%(1)

cathPatients1 = [];
cathPatients2 = [];
cathPatients3 = [];
bothPatients0 = [];
bothPatients1 = [];
bothPatients2 = [];
bothPatients3 = [];
infPatients0 = [];
infPatients1 = [];
infPatients2 = [];
infPatients00 = [];
infPatients11 = [];
N = 100;
O = 0;
P00 = 100;
P01 = 0;
P02 = 0;
P03 = 0;
P10 = 400;
P11 = 0;
P12 = 0;
P13 =0;
P20 = 250;
P21 = 0;
P22 =0;
P23 = 0;
I0 = 0;
I1 =0;
I2 = 0;
I00 = 0;
I11 = 0;
totalPop = N + O + P00 + P01 + P02 + P03 + P10 + P11 + ...
P12 + ...
P13 + P20 + P21 + P22 + P23 + I0 + I1 + I2 + I00 + I11;
dischargeMatrix = zeros(19,19);
deviceMatrix = zeros(19,19);
batheMatrix = zeros(19,19);
infectMatrix = zeros(19,19);
kitMatrix = zeros(19,19);
patientMatrix = zeros(19,1); %setting up the patient matrix
patientMatrix(1,1)=N;
patientMatrix(2,1)=O;
patientMatrix(3,1)=P00;
patientMatrix(4,1)=P01;
patientMatrix(5,1)=P02;
patientMatrix(6,1)=P03;
patientMatrix(7,1)=P10;
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patientMatrix(8,1)=P11;
patientMatrix(9,1)=P12;
patientMatrix(10,1)=P13;
patientMatrix(11,1)=P20;
patientMatrix(12,1)=P21;
patientMatrix(13,1)=P22;
patientMatrix(14,1)=P23;
patientMatrix(15,1)=I0;
patientMatrix(16,1)=I1;
patientMatrix(17,1)=I2;
patientMatrix(18,1) = I00;
patientMatrix(19,1) = I11;
for b=1:length(beta)
for w=1:length(betaStar)
bothinfections = [];
CAUTIinfections = [];
CLABSIinfections = [];

%probability of getting device
pN0 = getCL;
pN1 = getCath;
pN2 = getCLandCath;
pO0 = getCL;
pO1 = getCath;
pO2 = getCLandCath;
pO3 = getCLandCath;
p00 = getCLandCath;
p01 = getCLandCath;
p02 = getCLandCath;
p03 = getCLandCath;
p10 = getCLandCath;
p11 = getCLandCath;
p12 = getCLandCath;
p13 = getCLandCath;
t = years*daysInYear + ss ; %number of days the
simulation was run
%initial distribution of patients
N = 100;
O = 0;
P00 = 100;
P01 = 0;
P02 = 0;
P03 = 0;
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...

P10 = 400;
P11 = 0;
P12 = 0;
P13 =0;
P20 = 250;
P21 = 0;
P22 =0;
P23 = 0;
I0 = 0;
I1 =0;
I2 = 0;
I00 = 0;
I11 = 0;
%t = 730+300;
totalPop = N + O + P00 + P01 + P02 + P03 + P10
+ P11 + P12 + ...
P13 + P20 + P21 + P22 + P23 + I0 + I1 + I2
+ I00 + I11;
% % ----- discharge matrix ----%setting up the discharge matrix
dischargeMatrix(1,1) = 1;
dischargeMatrix(1,2) = ∆ Other;
dischargeMatrix(1,3) = ∆ CL;
dischargeMatrix(1,4) = ∆ CL;
dischargeMatrix(1,5) = ∆ CL;
dischargeMatrix(1,6) = ∆ CL;
dischargeMatrix(1,7) = ∆ Cath;
dischargeMatrix(1,8) = ∆ Cath;
dischargeMatrix(1,9) = ∆ Cath;
dischargeMatrix(1,10) = ∆ Cath;
dischargeMatrix(1,11) = ∆ CL;
dischargeMatrix(1,12) = ∆ CL;
dischargeMatrix(1,13) = ∆ CL;
dischargeMatrix(1,14) = ∆ CL;
dischargeMatrix(1,15) = ∆ CLinf;
dischargeMatrix(1,16) = ∆ Cathinf;
dischargeMatrix(1,17) = ∆ CLinf;
dischargeMatrix(1,18) = ∆ CLinf;
dischargeMatrix(1,19) = ∆ CLinf;
dischargeMatrix(2,2)
dischargeMatrix(3,3)
dischargeMatrix(4,4)
dischargeMatrix(5,5)
dischargeMatrix(6,6)
dischargeMatrix(7,7)

=
=
=
=
=
=
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1
1
1
1
1
1

-

Other;
CL;
∆ CL;
∆ CL;
∆ CL;
∆ Cath;
∆
∆

...
...

dischargeMatrix(8,8) =
dischargeMatrix(9,9) =
dischargeMatrix(10,10)
dischargeMatrix(11,11)
dischargeMatrix(12,12)
dischargeMatrix(13,13)
dischargeMatrix(14,14)
dischargeMatrix(15,15)
dischargeMatrix(16,16)
dischargeMatrix(17,17)
dischargeMatrix(18,18)
dischargeMatrix(19,19)

1
1
=
=
=
=
=
=
=
=
=
=

- ∆ Cath;
- ∆ Cath;
1 - ∆ Cath;
1 - ∆ CL;
1 - ∆ CL;
1 - ∆ CL;
1 - ∆ CL;
1 - ∆ CLinf;
1 - ∆ Cathinf;
1 - ∆ CLinf;
1 - ∆ CLinf;
1- ∆ CLinf;

% % ----- infection matrix ----infectMatrix(1,1) = 1;
infectMatrix(2,2) = 1;
infectMatrix(3,3) =
infectMatrix(4,4) =
infectMatrix(5,5) =
infectMatrix(6,6) =
infectMatrix(7,7) =
infectMatrix(8,8) =
infectMatrix(9,9) =
infectMatrix(10,10)
infectMatrix(11,11)
r10prime ;
infectMatrix(12,12)
r11prime ;
infectMatrix(13,13)
r12prime ;
infectMatrix(14,14)
r13prime ;
infectMatrix(15,15)
infectMatrix(16,16)
infectMatrix(17,17)
infectMatrix(18,18)
infectMatrix(19,19)
infectMatrix(15,3)
infectMatrix(15,4)
infectMatrix(15,5)
infectMatrix(15,6)

1
1
1
1
1
1
1
=
=

;
;
- r02;
- r03;
;
;
;
1 - r13 ;
1 - r20 - r00prime -

...

= 1 - r21 - r01prime -

...

= 1 - r22 - r02prime -

...

= 1 - r23 - r03prime -

...

=
=
=
=
=
=
=
=
=

1;
1;
1;
1 - rI0;
1- rI1;
0;
0;
r02;
r03;

infectMatrix(16,7) = 0;
infectMatrix(16,8) = 0;
infectMatrix(16,9) = 0;
infectMatrix(16,10) = r13;
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infectMatrix(15,11) = r00prime;
infectMatrix(16,11) = r10prime;
infectMatrix(17,11) = r20;
infectMatrix(15,12) = r01prime;
infectMatrix(16,12) = r11prime;
infectMatrix(17,12) = r21;
infectMatrix(15,13) = r02prime;
infectMatrix(16,13) = r12prime;
infectMatrix(17,13) = r22;
infectMatrix(15,14) = r03prime;
infectMatrix(16,14) = r13prime;
infectMatrix(17,14) = r23;
infectMatrix(17,18) = rI0;
infectMatrix(17,19) = rI1;

% % ----- bathing matrix -----

batheMatrix(2,1) = 1;
batheMatrix(3,2) = 1;
batheMatrix(3,3) = beta(b);
batheMatrix(4,3) = 1- beta(b);
batheMatrix(3,4) = beta(b);
batheMatrix(5,4) = 1-beta(b);
batheMatrix(3,5) = beta(b);
batheMatrix(6,5) = 1- beta(b);
batheMatrix(3,6) = beta(b);
batheMatrix(6,6) = 1-beta(b);
batheMatrix(7,7) = beta(b);
batheMatrix(8,7) = 1-beta(b);
batheMatrix(7,8) = beta(b);
batheMatrix(9,8) = 1-beta(b);
batheMatrix(7,9) = beta(b);
batheMatrix(10,9) = 1-beta(b);
batheMatrix(7,10) = beta(b);
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batheMatrix(10,10) = 1 - beta(b);
batheMatrix(11,11) = beta(b);
batheMatrix(12,11) = 1-beta(b);
batheMatrix(11,12) = beta(b);
batheMatrix(13,12) = 1- beta(b);
batheMatrix(11,13) = beta(b);
batheMatrix(14,13) = 1-beta(b);
batheMatrix(11,14) = beta(b);
batheMatrix(14,14) = 1 - beta(b);
batheMatrix(15,15)
batheMatrix(16,16)
batheMatrix(17,17)
batheMatrix(18,18)
batheMatrix(19,19)

=
=
=
=
=

1;
1;
1;
1;
1;

% % ----- device matrix -----deviceMatrix(1,1) = 1 - pN0 - pN1 - pN2;
deviceMatrix(2,2) = 1 - pO0 - pO1 - pO2;
deviceMatrix(3,1) = pN0;
deviceMatrix(3,2) = pO0;
deviceMatrix(3,3) = 1-p00;
deviceMatrix(4,4) = 1- p01;
deviceMatrix(5,5) = 1- p02;
deviceMatrix(6,6) = 1- p03;
deviceMatrix(7,7) = 1 - p10;
deviceMatrix(8,8) = 1 - p11;
deviceMatrix(9,9) = 1 - p12;
deviceMatrix(10,10) = 1 - p13;
deviceMatrix(7,1) = pN1;
deviceMatrix(7,2) = pO1;
deviceMatrix(11,1) = pN2;
deviceMatrix(11,2) = pO2;
deviceMatrix(11,3) = p00;
deviceMatrix(11,4) = p01;
deviceMatrix(11,5) = p02;
deviceMatrix(11,6) = p03;
deviceMatrix(11,7) = p10;
deviceMatrix(11,8) = p11;
deviceMatrix(11,9) = p12;
deviceMatrix(11,10) = p13;
deviceMatrix(11,11) = 1;
deviceMatrix(12,12) = 1;
deviceMatrix(13,13) = 1;
deviceMatrix(14,14) = 1;
deviceMatrix(15,15) = 1;
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deviceMatrix(16,16) =1;
deviceMatrix(17,17) =1;
deviceMatrix(18,18) = 1;
deviceMatrix(19,19)=1;
% % ----- central line standardized kit matrix
-----%setting up standardized kit matrix
kitMatrix(1,1) = 1;
kitMatrix(2,2) = 1;
kitMatrix(3,3) = betaStar(w);
kitMatrix(4,3) = 1- betaStar(w);
kitMatrix(3,4) = betaStar(w);
kitMatrix(5,4) = 1-betaStar(w);
kitMatrix(3,5) = betaStar(w);
kitMatrix(6,5) = 1- betaStar(w);
kitMatrix(3,6) = betaStar(w);
kitMatrix(6,6) = 1-betaStar(w);
kitMatrix(7,7) =
kitMatrix(8,8) =
kitMatrix(9,9) =
kitMatrix(10,10)

1;
1;
1;
= 1;

kitMatrix(11,11) = betaStar(w);
kitMatrix(12,11) = 1-betaStar(w);
kitMatrix(11,12) = betaStar(w);
kitMatrix(13,12) = 1- betaStar(w);
kitMatrix(11,13) = betaStar(w);
kitMatrix(14,13) = 1-betaStar(w);
kitMatrix(11,14) = betaStar(w);
kitMatrix(14,14) = 1 - betaStar(w);
kitMatrix(15,15)
kitMatrix(16,16)
kitMatrix(17,17)
kitMatrix(18,18)
kitMatrix(19,19)

=
=
=
=
=

1;
1;
1;
1;
1;

%
application1 =infectMatrix*deviceMatrix;
application2 = application1*batheMatrix;
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...

application3 = application2*kitMatrix;
application4 = application3*dischargeMatrix;
patientMatrix = application4*patientMatrix;
newPatients(b,1) = patientMatrix(1,1);
circPatients(b,1) = patientMatrix(2,1);
clPatients0(b,1) = patientMatrix(3,1);
clPatients1(b,1) = patientMatrix(4,1);
clPatients2(b,1) = patientMatrix(5,1);
clPatients3(b,1) = patientMatrix(6,1);
cathPatients0(b,1) = patientMatrix(7,1);
cathPatients1(b,1) = patientMatrix(8,1);
cathPatients2(b,1) = patientMatrix(9,1);
cathPatients3(b,1) = patientMatrix(10,1);
bothPatients0(b,1) = patientMatrix(11,1);
bothPatients1(b,1) = patientMatrix(12,1);
bothPatients2(b,1) = patientMatrix(13,1);
bothPatients3(b,1) = patientMatrix(14,1);
infPatients0(b,1) = patientMatrix(15,1);
infPatients1(b,1) = patientMatrix(16,1);
infPatients2(b,1) = patientMatrix(17,1);
infPatients00(b,1) = patientMatrix(18,1);
infPatients11(b,1) = patientMatrix(19,1);
ceil(patientMatrix); %rounding patient values up
end
end

newCAUTIInfectionsMatrix6Months = [];
newCAUTIInfectionsMatrix12Months = [];
newCAUTIInfectionsMatrix18Months = [];
newCAUTIInfectionsMatrix24Months = [];
newCAUTIInfectionsMatrix30Months = [];
newCAUTIInfectionsMatrix36Months = [];
newCAUTIInfectionsMatrix42Months = [];
newCAUTIInfectionsMatrix48Months = [];
newCAUTIInfectionsMatrix54Months = [];
newCAUTIInfectionsMatrix60Months = [];
newCAUTIInfectionsMatrix=[];
newCLABSIInfectionsMatrix6Months = [];
newCLABSIInfectionsMatrix12Months = [];
newCLABSIInfectionsMatrix18Months = [];
newCLABSIInfectionsMatrix24Months = [];
newCLABSIInfectionsMatrix30Months = [];
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newCLABSIInfectionsMatrix36Months
newCLABSIInfectionsMatrix42Months
newCLABSIInfectionsMatrix48Months
newCLABSIInfectionsMatrix54Months
newCLABSIInfectionsMatrix60Months
newCLABSIInfectionsMatrix=[];

=
=
=
=
=

[];
[];
[];
[];
[];

newBothInfectionsMatrix6Months = [];
newBothInfectionsMatrix12Months = [];
newBothInfectionsMatrix18Months = [];
newBothInfectionsMatrix24Months = [];
newBothInfectionsMatrix30Months = [];
newBothInfectionsMatrix36Months = [];
newBothInfectionsMatrix42Months = [];
newBothInfectionsMatrix48Months = [];
newBothInfectionsMatrix54Months = [];
newBothInfectionsMatrix60Months = [];
newBothInfectionsMatrix=[];

sixMonths = ceil(30.4*6)+ss; %calculating new infections
for p=(sixMonths - ss):sixMonths
newBothinfections6Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections6Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections6Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections6Months;
newCLABSIMatrix(p,1) = newCLABSIinfections6Months;
newCAUTIMatrix(p,1) = newCAUTIinfections6Months;
end
sixMonSumCLABSI = sum(newCLABSIMatrix(ss:sixMonths))
sixMonSumCAUTI = sum(newCAUTIMatrix(ss:sixMonths))
sixMonSumBoth = sum(newBothMatrix(ss:sixMonths))
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twelveMonths = 365+ss;
for p=sixMonths+1:twelveMonths
newBothinfections12Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections12Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections12Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections12Months;
newCLABSIMatrix(p,1) = newCLABSIinfections12Months;
newCAUTIMatrix(p,1) = newCAUTIinfections12Months;
end
twelveMonSumCLABSI = sum(newCLABSIMatrix(ss:twelveMonths))
twelveMonSumCAUTI = sum(newCAUTIMatrix(ss:twelveMonths))
twelveMonSumBoth = sum(newBothMatrix(ss:twelveMonths))
eighteenMonths = ceil(30.4*18)+ss;
for p=twelveMonths+1:eighteenMonths
newBothinfections18Months = ...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections18Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
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newCAUTIinfections18Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections18Months;
newCLABSIMatrix(p,1) = newCLABSIinfections18Months;
newCAUTIMatrix(p,1) = newCAUTIinfections18Months;
end
eighteenMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:eighteenMonths))
eighteenMonSumCAUTI = sum(newCAUTIMatrix(ss:eighteenMonths))
eighteenMonSumBoth = sum(newBothMatrix(ss:eighteenMonths))
twentyFourMonths = ceil(30.4*24)+ss;
for p=eighteenMonths+1:twentyFourMonths
newBothinfections24Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections24Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections24Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections24Months;
newCLABSIMatrix(p,1) = newCLABSIinfections24Months;
newCAUTIMatrix(p,1) = newCAUTIinfections24Months;
end
twentyFourMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:twentyFourMonths))
twentyFourMonSumCAUTI = ...
sum(newCAUTIMatrix(ss:twentyFourMonths))
twentyFourMonSumBoth = ...
sum(newBothMatrix(ss:twentyFourMonths))
thirtyMonths = ceil(30.4*30)+ss;
for p=twentyFourMonths+1:thirtyMonths
newBothinfections30Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
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+

+ bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections30Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections30Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections30Months;
newCLABSIMatrix(p,1) = newCLABSIinfections30Months;
newCAUTIMatrix(p,1) = newCAUTIinfections30Months;
end
thirtyMonSumCLABSI = sum(newCLABSIMatrix(ss:thirtyMonths))
thirtyMonSumCAUTI = sum(newCAUTIMatrix(ss:thirtyMonths))
thirtyMonSumBoth = sum(newBothMatrix(ss:thirtyMonths))
thirtySixMonths = ceil(30.4*36)+ss;
for p=thirtyMonths+1:thirtySixMonths
newBothinfections36Months = ...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections36Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections36Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections36Months;
newCLABSIMatrix(p,1) = newCLABSIinfections36Months;
newCAUTIMatrix(p,1) = newCAUTIinfections36Months;
end
thirtySixMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:thirtySixMonths))
thirtySixMonSumCAUTI = ...
sum(newCAUTIMatrix(ss:thirtySixMonths))
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thirtySixMonSumBoth = sum(newBothMatrix(ss:thirtySixMonths))
fortyTwoMonths = ceil(30.4*42)+ss;
for p=thirtySixMonths+1:fortyTwoMonths
newBothinfections42Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections42Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections42Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections42Months;
newCLABSIMatrix(p,1) = newCLABSIinfections42Months;
newCAUTIMatrix(p,1) = newCAUTIinfections42Months;
end
fortyTwoMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:fortyTwoMonths))
fortyTwoMonSumCAUTI = sum(newCAUTIMatrix(ss:fortyTwoMonths))
fortyTwoMonSumBoth = sum(newBothMatrix(ss:fortyTwoMonths))
fortyEightMonths = ceil(30.4*48)+ss;
for p=fortyTwoMonths+1:fortyEightMonths
newBothinfections48Months = ...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections48Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections48Months = cathPatients0(p)*r10 + ...
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cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections48Months;
newCLABSIMatrix(p,1) = newCLABSIinfections48Months;
newCAUTIMatrix(p,1) = newCAUTIinfections48Months;
end
fortyEightMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:fortyEightMonths))
fortyEightMonSumCAUTI = ...
sum(newCAUTIMatrix(ss:fortyEightMonths))
fortyEightMonSumBoth = ...
sum(newBothMatrix(ss:fortyEightMonths))
fiftyFourMonths = ceil(30.4*54)+ss;
for p=fortyEightMonths+1:fiftyFourMonths
newBothinfections54Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
+ + bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections54Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections54Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections54Months;
newCLABSIMatrix(p,1) = newCLABSIinfections54Months;
newCAUTIMatrix(p,1) = newCAUTIinfections54Months;
end
fiftyFourMonSumCLABSI = ...
sum(newCLABSIMatrix(ss:fiftyFourMonths))
fiftyFourMonSumCAUTI = ...
sum(newCAUTIMatrix(ss:fiftyFourMonths))
fiftyFourMonSumBoth = sum(newBothMatrix(ss:fiftyFourMonths))
sixtyMonths = ceil(30.4*60)+ss;
for p=fiftyFourMonths+1:sixtyMonths
newBothinfections60Months =
...
bothPatients0(p)*r00prime + ...
bothPatients1(p)*r01prime ...
+ bothPatients2(p)*r02prime + ...
bothPatients3(p)*r03prime ...
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+

+ bothPatients0(p)*r10prime + ...
bothPatients1(p)*r11prime ...
+ bothPatients2(p)*r12prime + ...
bothPatients3(p)*r13prime ...
+ bothPatients0(p)*r20 + bothPatients1(p)*r21 ...
+ bothPatients2(p)*r22 + bothPatients3(p)*r23 + ...
infPatients00(p)*rI0 ...
+ infPatients11(p)*rI1;
newCLABSIinfections60Months = clPatients0(p)*r00+ ...
clPatients1(p)*r01+ clPatients2(p)*r02 + ...
clPatients3(p)*r03 ;
newCAUTIinfections60Months = cathPatients0(p)*r10 + ...
cathPatients2(p)*r12 + cathPatients1(p)*r11+ ...
cathPatients3(p)*r13 ;
newBothMatrix(p,1) = newBothinfections60Months;
newCLABSIMatrix(p,1) = newCLABSIinfections60Months;
newCAUTIMatrix(p,1) = newCAUTIinfections60Months;
end
sixtyMonSumCLABSI = sum(newCLABSIMatrix(ss:sixtyMonths))
sixtyMonSumCAUTI = sum(newCAUTIMatrix(ss:sixtyMonths))
sixtyMonSumBoth = sum(newBothMatrix(ss:sixtyMonths))
oppBetaVector = 1 - beta;
numberOfBaths = 850*sum(beta);
numberOfNonCHGBaths = 850*sum(oppBetaVector);
numberOfKits = 850*(sum(bothPatients0(ss:sixtyMonths)) ...
+ sum(bothPatients1(ss:sixtyMonths)) + ...
sum(bothPatients2(ss:sixtyMonths))...
+ sum(bothPatients3(ss:sixtyMonths)) + ...
sum(clPatients0(ss:sixtyMonths)) + ...
sum(clPatients1(ss:sixtyMonths)) + ...
sum(clPatients2(ss:sixtyMonths)) + ...
sum(clPatients3(ss:sixtyMonths)))
printVectorCLABSI = [];
printVectorCAUTI = [];
printVectorBoth = [];
printVectorCLABSI = [printVectorCLABSI; sixMonSumCLABSI ...
twelveMonSumCLABSI eighteenMonSumCLABSI ...
twentyFourMonSumCLABSI thirtyMonSumCLABSI ...
thirtySixMonSumCLABSI fortyTwoMonSumCLABSI ...
fortyEightMonSumCLABSI fiftyFourMonSumCLABSI ...
sixtyMonSumCLABSI];
printVectorCAUTI = [printVectorCAUTI; sixMonSumCAUTI ...
twelveMonSumCAUTI eighteenMonSumCAUTI ...
twentyFourMonSumCAUTI thirtyMonSumCAUTI ...
thirtySixMonSumCAUTI fortyTwoMonSumCAUTI ...
fortyEightMonSumCAUTI fiftyFourMonSumCAUTI ...
sixtyMonSumCAUTI];
printVectorBoth = [printVectorBoth; sixMonSumBoth ...
twelveMonSumBoth eighteenMonSumBoth ...
twentyFourMonSumBoth thirtyMonSumBoth ...
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thirtySixMonSumBoth fortyTwoMonSumBoth ...
fortyEightMonSumBoth fiftyFourMonSumBoth ...
sixtyMonSumBoth];
printVector = [printVectorBoth; printVectorCAUTI;
printVectorCLABSI];
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Appendix D

MATLAB CODE – SIR MODEL

% SIR Model
S0 = 4500000;
I0 = 2;
R0 = 0;
p0 = [S0 I0 R0];
tspan = 0:530;
[t,p] = ode15s(@Popmodel, tspan, p0);
%
S
I
R

Plot
= p(:,1);
= p(:,2);
= p(:,3);

figure(1)
hold on
plot(t, S,'LineWidth',3);
plot(t, I,'LineWidth',3);
plot(t, R,'LineWidth',3);
legend('S','I','R')
xlabel('Time')
ylabel('Number of Individuals')
title('SIR Model')
hold off
% Function Definitions
function pdot = Popmodel(t,u)
%Parameters for SIR Model
d = 14;
S = u(1);
I = u(2);
R = u(3);
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beta = transmission(t); %beta is time dependent
dS = -beta*S*I; %SIR equations
dI = beta*S*I - (1/d)*I;
dR = (1/d)*I;
pdot=[dS dI dR]';
end
function y = beta1(t)
betah = 0.0000006; %transmission due to hospital
Eh = 0.8; %effectiveness of PPE
tH = 50; %time when PPE runs out
if t ≤ tH
y = betah*Eh;
else
y = betah;
end
end
function y = beta2(t)
betas = 0.00000006; %transmission due to community
Es = 0.6; %effectiveness of social distancing
tS = 45; %time when social distancing starts
if t ≤ tS
y = betas;
else
y = betas*Es;
end
end
function beta = transmission(t)
h = 0.1;
beta = beta1(t)*h + beta2(t)*(1-h);
end
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Appendix E

MATLAB CODE – NON-ADI MODEL

clear

%----------------------------------------------------------------------%
PARAMETERS
%----------------------------------------------------------------------endSim = 1;
yearlyInfectionCounter(1) = 0;
testsYearly = [];
double = 2;
half = 0.5;
ad = 1;
for w=1 :endSim
endTime = 6*365; %10*365;
burnInYear = 1;
adjustTime = 1*365; %run program for this long
before making calculatio;ns
tt = endTime + adjustTime;
newInfection = zeros(tt,1);
hospInfection1 = zeros(tt,1);
commInfection1 = zeros(tt,1);
tests = 0;

...

%CANNOT ADJUST - LIT VALUES
gamma = 1/10*ad; %recovery from C.diff,
tau = 1;
lambda = 1/6*ad; %likelihood of being prescribed ...
antibiotics
theta1 = 1/10*ad;
b = 0.8; % proportion of patients coming in susceptible
%CAN ADJUST
sigma1 = 0.01*ad; %becoming colonized from susceptible
sigma2 = 0.05*ad; %becoming colonized from ...
susceptible on antibiotics
theta2 = 1/60*ad; % moving from colonized in ...
hospital to infectious
theta3 = 1/60*ad;
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alphaCA = 1;%1.06;
alphaC = 1;%1.06;
alphaCH = 1;%1.06;
alphaIN = 2;
alphaIS = 1;%1.03;
alphaR = 1; %1.015;
alphaD = 1;% 1.1;
alpha = 1;
enCo = 1000/ad;
enviroBoost = 6;

%------------------------------------------------------------------%
INITIALIZING PATIENT STATES & ENVIRONMENT
%------------------------------------------------------------------% S = 1, SA = 2, % Ca = 3, C = 4, IN = 5, IS = 6, R
= 7, CH = 8

...

p1 = 1;
p2 = 1;
p3 = 1;
p4 = 1;
p5 = 1;
p6 = 1;
p7 = 1;
p8 = 1;
p9 = 1;
p10 = 1;
p11 = 1;
p12 = 1;
p13 = 1;
p14 = 1;
p15 = 1;
p16 = 2;
p17 = 2;
p18 = 2;
p19 = 2;
p20 = 2;
p21 = 2;
vector = [p1; p2; p3; p4; p5; p6; p7; p8; p9; p10; ...
p11; p12; p13; p14; p15; p16; p17; p18; p19; ...
p20; p21];
vectorNames = {'p1'; 'p2'; 'p3'; 'p4'; 'p5'; 'p6'; ...
'p7'; 'p8'; 'p9'; 'p10'; 'p11'; 'p12'; 'p13'; ...
'p14'; 'p15'; 'p16'; 'p17'; 'p18'; 'p19'; 'p20'; ...
'p21'};
P(1) = 0;
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probPath(1) = 0;
array = zeros(length(vector) , endTime, 4);
array(:,1,1) = vector;
numPatients = size(vector);
initialLOS = [randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); randi([0,42],1)];
array(:,1,2) = initialLOS;

%tests = zeros(numPatients(1),tt);
%------------------------------------------------------------------%
BIG LOOP ITERATING THROUGH PATIENTS ON ...
INSIDE (i)
%
AND DAY SIMULATION ON THE OUTSIDE (j)
%------------------------------------------------------------------for j=2:(tt)
for i=1:numPatients %want to iterate this over
entire vector except for environment

...

%----------------------------------------------------------%
SETTING UP RANDOM NUMBERS TO BE ...
USED BELOW
%----------------------------------------------------------r0
r1
r2
r3
r4
r5
r6
r7
r8

=
=
=
=
=
=
=
=
=

rand();
rand();
rand();
rand();
rand();
rand();
rand();
rand();
rand();

%----------------------------------------------------------%
ADDING TO THE LOS
%----------------------------------------------------------array(i,j,2) = array(i,j-1,2) + 1;
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%----------------------------------------------------------%
PATIENT TRANSITION STATEMENTS
%----------------------------------------------------------if array(i,j-1,1) == 0
%array(i,j,2) = 0;
if r0 ≥ 0.2
array(i,j,1) = 1;
else
array(i,j,1) = 4;
end
elseif array(i,j-1,1) == 1 %patient is in S
if r1 ≥ 0 && r1 < lambda
array(i,j,1) = 2;
elseif r1 ≥ lambda && r1 < lambda + ...
sigma1*probPath(j-1)
array(i,j,1) = 8;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 2 %patient is in SA
if r2 ≥ 0 && r2 < sigma2*probPath(j-1)
array(i,j,1) = 3;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 3 %patient is in CA
if r3 ≥ 0 && r3 < theta1
array(i,j,1) = 5;
newInfection(j,1) = ...
newInfection(j,1) + 1;
hospInfection1(j,1) = ...
hospInfection1(j,1) + 1;
%tests(i,j) = 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 4 %patient is in C
if r4 ≥ 0 && r4 < theta3
array(i,j,1) = 5;
newInfection(j,1) = ...
newInfection(j,1) + 1;
commInfection1(j,1) = ...
commInfection1(j,1) + 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
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end
elseif array(i,j-1,1) == 5 %patient is in IN
if r5 ≥ 0 && r5 < tau
array(i,j,1) = 6;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 6 %patient is in IS
if r6 ≥ 0 && r6 < gamma
array(i,j,1) = 7;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 8 %patient is in CH
if r8 ≥ 0 && r8 < theta2
array(i,j,1) = 5;
newInfection(j,1) = ...
newInfection(j,1) + 1;
hospInfection1(j,1) = ...
hospInfection1(j,1) + 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
end
else %patient is in R
array(i,j,1) = array(i,j-1,1);
end

%----------------------------------------------------------%
DISCHARGE CALCULATIONS
%----------------------------------------------------------disNum = 0.8;
disNum2 = 0.9;
if array(i,j,2) > 42 && (array(i,j,3) > 14 ...
| | array(i,j,3) ==0) %array(i,j-1,3) > ...
14
%want to make sure that
%people haven't gotten sick or recovered
%reset LOS counter here, reset page 3 here
if array(i,j,1) == 1 && rand() <
disNum2 % ∆ S
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...

array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
elseif array(i,j,1) == 2 && rand() <
disNum2 % ∆ SA
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

elseif array(i,j,1) == 3 && rand()<
disNum % ∆ CA
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

elseif array(i,j,1) == 4 && rand()<
0.99 % ∆ C
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

elseif array(i,j,1) == 7 && rand() <
disNum % ∆ R
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

elseif array(i,j,1) == 8 && rand() <
disNum2 % ∆ CH
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

end
elseif array(i,j,2) > 56 && array(i,j,1)==7
%person may have been sick or recovered
if rand()< disNum2 % ∆ R + dR
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
% disp('sick discharge')
end
else

...

end
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%
CALCULATING NEW INFECTIONS
%----------------------------------------------------------if mod(j,30)==0
monthCount = j/30;
cumulative30DaySumInfected(w,monthCount)
= sum(newInfection(j-29:j));

...

end
if mod(j,365) ==0
m2 = j/365;
yearlyInfectionCounter(w,m2) =
sum(newInfection(j-364:j));

...

end

%----------------------------------------------------------%
CALCULATING LENGTH OF ...
INFECTIONS PATIENTS
%----------------------------------------------------------if array(i,j-1,1)==6 | | array(i,j-1,1)==5
%counting sick LOS
array(i,j,3) = array(i,j-1,3) + 1;
end

...

end

%----------------------------------------------------------%
COUNTING PATIENTS IN EACH CLASS ...
ON EACH DAY
%----------------------------------------------------------countDischarge = sum(array(:,:,1)==0,1);
countS = sum(array(:,:,1)==1,1);
countSA = sum(array(:,:,1)==2,1);
countCA = sum(array(:,:,1)==3,1);
countC = sum(array(:,:,1)==4,1);
countIN = sum(array(:,:,1)==5,1);
countIS = sum(array(:,:,1)==6,1);
countR = sum(array(:,:,1)==7,1);
countCH = sum(array(:,:,1)==8,1);

%----------------------------------------------------------%
YEARLY DISCHARGE COUNT
%----------------------------------------------------------if

mod(j,365) ==0
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m2 = j/365;
sumCountDischarge(w,m2) = ...
sum(countDischarge(j-364:j));
testsYearly = [testsYearly; tests];
tests = 0;
end

%--------------------------------------------------------------%
ENVIRONMENT AND PROPORTION OF ...
ENVIRONMENT CONTAMINATED
%
CALCULATIONS
%--------------------------------------------------------------P(j) = max(0.4*P(j-1) +alphaCH*countCH(j) ...
+alphaCA*countCA(j) + alphaC*countC(j) + ...
alphaIN*countIN(j) + alphaIS*countIS(j) + ...
alphaR*countR(j) - alphaD*countDischarge(j),0);
probPath(j) = (alpha*enviroBoost*P(j))/(enCo + ...
alpha*enviroBoost*P(j));
end

%-----------------------------------------------------------------%
YEARLY MEANS AND ST DEVS CALCULATIONS
%------------------------------------------------------------------for q=1:length(cumulative30DaySumInfected)
if mod(q,12)==0
yearCount = q/12;
yearlyMean(w,yearCount) = ...
mean(cumulative30DaySumInfected(q-11:q));
yearlyStDev(w,yearCount) = ...
std(cumulative30DaySumInfected(q-11:q));
end
end
for r=1:tt
if mod(r,365) ==0
m3 = r/365;
hospInfYearly(w,m3) = sum(hospInfection1(r-364:r));
commInfYearly(w,m3) = sum(commInfection1(r-364:r));
%testsYearly(w,m3) = sum(tests(r-364:r));
end
end
hospInfSum(w,1) = sum(hospInfYearly(w,:));
commInfSum(w,1) = sum(commInfYearly(w,:));
totalInfSum(w,1) = hospInfSum(w,1) + commInfSum(w,1);
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for v=1:tt
if mod(v,30)==0
m4 = v/30;
hospInfMonthly(w,m4) = sum(hospInfection1(v-29:v));
commInfMonthly(w,m4) = sum(commInfection1(v-29:v));
totalInfMonthly(w,m4) = hospInfMonthly(w,m4) + ...
commInfMonthly(w,m4);
end
end

%----------------------------------------------------------------------%
COUNTING NUMBER OF TESTS AND ALL INFECTIONS
%----------------------------------------------------------------------numberOfTests(w,1) = ...
sum(countIN(adjustTime+1 :endTime+adjustTime));
allInfections(w,1) = ...
sum(newInfection(adjustTime+1 :endTime+adjustTime));
hospInfection1([1:adjustTime],:) = [];
commInfection1([1:adjustTime],:) = [];
allHospInfPercent(w,1) = sum(hospInfection1) /
allInfections(w,1);
allCommInfPercent(w,1) = sum(commInfection1) /
allInfections(w,1);

...
...

%testSave = [testSave; tests];
end

%----------------------------------------------------------------------%
GETTING RID OF BURN IN YEAR
%----------------------------------------------------------------------yearlyInfectionCounter(:,[1:burnInYear]) = [];
yearlyMean(:,[1:burnInYear]) = [];
yearlyStDev(:,[1:burnInYear]) = [];
sumCountDischarge(:,[1:burnInYear]) = [];
hospInfYearly(:,[1:burnInYear]) = [];
commInfYearly(:,[1:burnInYear]) = [];
commInfMonthly(:,[1:12*burnInYear+1]) = [];
cumulative30DaySumInfected(:,[1:12*burnInYear+1]) = [];
hospInfMonthly(:,[1:12*burnInYear+1]) = [];
allYearsInfectionsMeans =
...
mean(yearlyInfectionCounter,'all');
allYearsInfectionsStDev = ...
std(yearlyInfectionCounter,0,'all');
allMonthsInfectionsMeans =

...
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mean(cumulative30DaySumInfected,'all');
allMonthsInfectionsStDev = ...
std(cumulative30DaySumInfected,0,'all');
allYearsHospInfMeanPercent = mean(allHospInfPercent, 'all');
allYearsHospInfCountMean = mean(hospInfYearly, 'all');
allYearsCommInfMeanPercent = mean(allCommInfPercent, 'all');
allYearsCommCountMean = mean(commInfYearly, 'all');
%testsYearly(:,[1:burnInYear]) = [];
%testYearlySum = sum(testsYearly');
%allYearlyMeanTests = mean(testsYearly,'all');
for b=1:length(testsYearly)
if mod(b,11) == 1
testsYearly(b) = nan;
end
end
allYearsAvTests = nanmean(testsYearly);
aa = [allYearsCommInfMeanPercent; ...
allYearsHospInfMeanPercent; allYearsCommCountMean; ...
allYearsHospInfCountMean; allMonthsInfectionsMeans; ...
allMonthsInfectionsStDev; allYearsInfectionsMeans; ...
allYearsInfectionsStDev; allYearsAvTests];
aa = aa';
countHospCol = countCH + countCA;
x = [1:1:366];
%
%
%
%
%
%
%
%

figure
plot(x,P)
legend('Amount of Pathogen')
figure
plot(x,probPath,'r')
legend('proportion of pathogen in environment')

figure
plot(x,countHospCol(:,[365:730],1), 'r', x,
countC(:,[365:730],1), 'm', ...
x,countIN(:,[365:730],1), 'b', x, ...
countIS(:,[365:730],1), 'c')
legend('Hospital-onset, Colonized', ...
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...

'Community-acquried, Colonized', 'Infected, not
tested', 'Infected, positive test')
xlabel('Time (days)');
ylabel('Number of patients');
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...

Appendix F

MATLAB CODE – ADI- MODEL

clear

%----------------------------------------------------------------------%
PARAMETERS
%----------------------------------------------------------------------endSim = 1;
yearlyInfectionCounter(1) = 0;
testsYearly = [];
double = 2;
half = 0.5;
for w=1 :endSim
endTime = 6*365;
burnInYear = 1;
adjustTime = 365; %run program for this long before
making calculations
tt = endTime + adjustTime;
newInfection = zeros(tt,1);
hospInfection1 = zeros(tt,1);
commInfection1 = zeros(tt,1);
tests = 0;
cleanRoom = 0;

...

%CANNOT ADJUST - LIT VALUES
gamma = 1/10; %recovery from C.diff,
tau = 1; %testing accuracy
lambda = 1/6;
theta1 = 1/10;
b = 0.8; % proportion of patients coming in susceptible
%CAN ADJUST
sigma1 = 0.01; %becoming colonized from susceptible
sigma2 = 0.05; %becoming colonized from ...
susceptible on antibiotics
theta2 = 1/60; % moving from colonized in hospital ...
to infectious
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theta4 = 1/60;
alphaCA = 1;%1.06;
alphaCS = 1;%;1.06;
alphaCH = 1;%1.06;
alphaIN = 2;
alphaIS = 1;%;1.03;
alphaR = 1;%1.015;
alphaD = 1;%1.1;
alpha = 1;
enCo = 1000;
enviroBoost = 6;

%------------------------------------------------------------------%
INITIALIZING PATIENT STATES & ENVIRONMENT
%------------------------------------------------------------------% S = 1, SA = 2, CA = 3, CH = 4, IN = 5, CS = 6, IS
= 7, R = 8

...

p1 = 1;
p2 = 1;
p3 = 1;
p4 = 1;
p5 = 1;
p6 = 1;
p7 = 1;
p8 = 1;
p9 = 1;
p10 = 1;
p11 = 1;
p12 = 1;
p13 = 1;
p14 = 1;
p15 = 1;
p16 = 2;
p17 = 2;
p18 = 2;
p19 = 2;
p20 = 2;
p21 = 3;
vector = [p1; p2; p3; p4; p5; p6; p7; p8; p9; p10; ...
p11; p12; p13; p14; p15; p16; p17; p18; p19; ...
p20; p21];
vectorNames = {'p1'; 'p2'; 'p3'; 'p4'; 'p5'; 'p6'; ...
'p7'; 'p8'; 'p9'; 'p10'; 'p11'; 'p12'; 'p13'; ...
'p14'; 'p15'; 'p16'; 'p17'; 'p18'; 'p19'; 'p20'; ...
'p21'};
P(1) = 0;
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probPath(1) = 0;
array = zeros(length(vector) , endTime, 4);
array(:,1,1) = vector;
numPatients = size(vector);
initialLOS = [randi([0,42],1);randi([0,42],1);
randi([0,42],1); ...
randi([0,42],1);randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1); ...
randi([0,42],1); randi([0,42],1)];
array(:,1,2) = initialLOS;

...

%------------------------------------------------------------------%
BIG LOOP ITERATING THROUGH PATIENTS ON ...
INSIDE (i)
%
AND DAY SIMULATION ON THE OUTSIDE (j)
%------------------------------------------------------------------for j=2:(tt)
for i=1:numPatients %want to iterate this over
entire vector except for environment
r0 = rand();
r1 = rand();
r2 = rand();
r3 = rand();
r4 = rand();
r5 = rand();
r6 = rand();
r7 = rand();

...

%----------------------------------------------------------%
ADDING TO THE LOS
%----------------------------------------------------------array(i,j,2) = array(i,j-1,2) + 1;

%----------------------------------------------------------%
PATIENT TRANSITION STATEMENTS
%----------------------------------------------------------if array(i,j-1,1) == 0
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if r0 ≥ 0.2
array(i,j,1) = 1;
tests = tests + 1;
else
array(i,j,1) = 6;
tests = tests + 1;
end
elseif array(i,j-1,1) == 1 %if patient is ...
in S
if r1 ≥ 0 && r1 < sigma1*probPath(j-1) ...
%go to 3 via sigma with environment ...
weight factored in
array(i,j,1) = 4;
elseif r1 ≥ sigma1*probPath(j-1) && r1 ...
< sigma1*probPath(j-1) + lambda %go ...
to 2 via lambda
array(i,j,1) = 2;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 2 %if patient is
in SA

...

if r2 ≥ 0 && r2 < sigma2*probPath(j-1)
array(i,j,1) = 3; %go to 4 via beta ...
with environment weight factored in
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 3 %if patient is
in CA
if r3 ≥ 0 && r3 < theta1
array(i,j,1) = 5;
newInfection(j,1) = ...
newInfection(j,1) + 1;
hospInfection1(j,1) = ...
hospInfection1(j,1) + 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
end

...

elseif array(i,j-1,1) == 4 %if patient is
in CH
if r4 ≥ 0 && r4 < theta2
array(i,j,1) = 5;
newInfection(j,1) = ...
newInfection(j,1) + 1;
hospInfection1(j,1) = ...

...

116

hospInfection1(j,1) + 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1) == 5 %if patient is
in IN
if r5 ≥ 0 && r5 < tau
array(i,j,1) = 7;
%newInfection(j,1) = ...
newInfection(j,1) + 1;
else
array(i,j,1) = array(i,j-1,1);
end

...

elseif array(i,j-1,1)==6 % patient is in CS
if r6 ≥ 0 && r6 < theta4
array(i,j,1) = 7;
newInfection(j,1) = ...
newInfection(j,1) + 1;
commInfection1(j,1) = ...
commInfection1(j,1) + 1;
tests = tests + 1;
else
array(i,j,1) = array(i,j-1,1);
end
elseif array(i,j-1,1)==7 %patient is in IS
if r7 ≥ 0 && r7 < gamma
array(i,j,1) = 8;
else
array(i,j,1) = array(i,j-1,1);
end
else %if patient is in R
array(i,j,1) = array(i,j-1,1);
end

%----------------------------------------------------------%
DISCHARGE CALCULATIONS
%----------------------------------------------------------disNum = 0.8;
disNum2 = 0.9;
if array(i,j,2) > 42 && (array(i,j,3) > 14 ...
| | array(i,j,3) ==0) %array(i,j-1,3) > ...
14
%want to make sure that
%people haven't gotten sick or recovered
%reset LOS counter here, reset page 3 here
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if array(i,j,1) ==
% ∆ S + dS
array(i,j,1) =
array(i,j,2) =
array(i,j,3) =

1 && rand() < disNum

...

0;
0;
0;

%disp('discharge from 1')
elseif array(i,j,1) == 2 && rand() <
disNum % ∆ SA + dSA
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
%disp('discharge from 2')
elseif array(i,j,1) == 3 && rand()<
disNum % ∆ C + dC
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;

...

...

%disp('discharge from 3')
elseif array(i,j,1) == 4 && rand()< disNum
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
elseif array(i,j,1) == 6 && rand()< disNum
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
if j > 365
cleanRoom = cleanRoom + 1;
end
elseif array(i,j,1) == 8 && rand() < disNum
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
%disp('discharge from 6')
end
elseif array(i,j,2) > 56 && array(i,j,1)==8
%person may have been sick or recovered
if rand()< disNum2 % ∆ R + dR
array(i,j,1) = 0;
array(i,j,2) = 0;
array(i,j,3) = 0;
%disp('sick discharge')
end
else
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...

%disp(array(i,j-1,2))
%disp(array(i,j-1,1))
end

%----------------------------------------------------------%
CALCULATING NEW INFECTIONS
%----------------------------------------------------------if mod(j,30)==0
monthCount = j/30;
cumulative30DaySumInfected(w,monthCount)
= sum(newInfection(j-29:j));
end
if mod(j,365) ==0
m2 = j/365;
yearlyInfectionCounter(w,m2) =
sum(newInfection(j-364:j));

...

...

end

%----------------------------------------------------------%
CALCULATING LENGTH OF ...
INFECTIONS PATIENTS
%----------------------------------------------------------if array(i,j-1,1)==5 | | array(i,j-1,1)==7
%counting sick LOS
array(i,j,3) = array(i,j-1,3) + 1;
end

...

end

%--------------------------------------------------------------%
COUNTING PATIENTS IN EACH CLASS ON ...
EACH DAY
%--------------------------------------------------------------countDischarge = sum(array(:,:,1)==0,1);
countS = sum(array(:,:,1)==1,1);
countSA = sum(array(:,:,1)==2,1);
countCA = sum(array(:,:,1)==3,1);
countCH = sum(array(:,:,1)==4,1);
countIN = sum(array(:,:,1)==5,1);
countCS = sum(array(:,:,1) ==6,1);
countIS = sum(array(:,:,1)==7,1);
countR = sum(array(:,:,1)==8,1);

%--------------------------------------------------------------119

%
YEARLY DISCHARGE COUNT
%--------------------------------------------------------------if

mod(j,365) ==0
m2 = j/365;
sumCountDischarge(w,m2) = ...
sum(countDischarge(j-364:j));
testsYearly = [testsYearly; tests];
tests = 0;

end

%--------------------------------------------------------------%
ENVIRONMENT AND PROPORTION OF ...
ENVIRONMENT CONTAMINATED
%
CALCULATIONS
%--------------------------------------------------------------P(j) = max(0.4*P(j-1) + alphaCA*countCA(j) ...
+alphaCH*countCH(j) + alphaCS*countCS(j) + ...
alphaIN*countIN(j) + alphaIS*countIS(j) + ...
alphaR*countR(j) - alphaD*countDischarge(j),0);
probPath(j) = (alpha*P(j))/(enCo + alpha*P(j));
end

%------------------------------------------------------------------%
YEARLY MEANS AND ST DEVS CALCULATIONS
%------------------------------------------------------------------for k=1:length(cumulative30DaySumInfected)
if mod(k,12)==0
yearCount = k/12;
yearlyMean(w,yearCount) = ...
mean(cumulative30DaySumInfected(k-11:k));
yearlyStDev(w,yearCount) = ...
std(cumulative30DaySumInfected(k-11:k));
end
end
for r=1:tt
if mod(r,365) ==0
m3 = r/365;
hospInfYearly(w,m3) = ...
sum(hospInfection1(r-364:r));
commInfYearly(w,m3) = ...
sum(commInfection1(r-364:r));
% testsYearly(w,m3) = sum(tests(r-364:r));
end
end
hospInfSum(w,1) = sum(hospInfYearly(w,:));
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commInfSum(w,1) = sum(commInfYearly(w,:));
totalInfSum(w,1) = hospInfSum(w,1) + commInfSum(w,1);

for v=1:tt
if mod(v,30)==0
m4 = v/30;
hospInfMonthly(w,m4) = ...
sum(hospInfection1(v-29:v));
commInfMonthly(w,m4) = ...
sum(commInfection1(v-29:v));
totalInfMonthly(w,m4) = ...
hospInfMonthly(w,m4) + commInfMonthly(w,m4);
end
end
%------------------------------------------------------------------%
COUNTING NUMBER OF TESTS AND ALL INFECTIONS
%----------------------------------------------------------------------allInfections(w,1) = sum(newInfection(adjustTime+1:tt));
hospInfection1([1:adjustTime],:) = [];
commInfection1([1:adjustTime],:) = [];
allHospInfPercent(w,1) = sum(hospInfection1) /
allInfections(w,1);
allCommInfPercent(w,1) = sum(commInfection1) /
allInfections(w,1);

...
...

end

%----------------------------------------------------------------------%
GETTING RID OF BURN IN YEAR
%----------------------------------------------------------------------yearlyInfectionCounter(:,[1:burnInYear]) = [];
yearlyMean(:,[1:burnInYear]) = [];
yearlyStDev(:,[1:burnInYear]) = [];
sumCountDischarge(:,[1:burnInYear]) = [];
hospInfYearly(:,[1:burnInYear]) = [];
commInfYearly(:,[1:burnInYear]) = [];
commInfMonthly(:,[1:12*burnInYear+1]) = [];
cumulative30DaySumInfected(:,[1:12*burnInYear+1]) = [];
hospInfMonthly(:,[1:12*burnInYear+1]) = [];
allYearsInfectionsMeans =
...
mean(yearlyInfectionCounter,'all');
allYearsInfectionsStDev = ...
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std(yearlyInfectionCounter,0,'all');
allMonthsInfectionsMeans = ...
mean(cumulative30DaySumInfected,'all');
allMonthsInfectionsStDev = ...
std(cumulative30DaySumInfected,0,'all');
allYearsHospInfMeanPercent = mean(allHospInfPercent, 'all');
allYearsHospInfCountMean = mean(hospInfYearly, 'all');
allYearsCommInfMeanPercent = mean(allCommInfPercent, 'all');
allYearsCommCountMean = mean(commInfYearly, 'all');
for b=1:length(testsYearly)
if mod(b,11) == 1
testsYearly(b) = nan;
end
end
allYearsAvTests = nanmean(testsYearly);
aa = [allYearsCommInfMeanPercent; ...
allYearsHospInfMeanPercent; allYearsCommCountMean; ...
allYearsHospInfCountMean; allMonthsInfectionsMeans; ...
allMonthsInfectionsStDev; allYearsInfectionsMeans; ...
allYearsInfectionsStDev; allYearsAvTests];
aa = aa';
countHospCol = countCH + countCA;
%x = [1:1:j-364];
x = [1:1:366];
%
%
%
%
%
%
%
%
%
%
%

figure
plot(x,P)
legend('Amount of Pathogen')
figure
plot(x,probPath,'r')
legend('proportion of pathogen in environment')

figure
plot(x,countS(:,:,1), x,countSA(:,:,1), ...
x,countCA(:,:,1), x,countCN(:,:,1), x, ...
countCS(:,:,1), x,countIN(:,:,1), x, countIS(:,:,1), ...
x, countR(:,:,1))
% legend('Susceptible','Susceptible on Antibiotics', ...
'Colonized on antibiotics', 'Colonized, not ...
screened', 'Colonized, screened','Infected, not ...
screened','Infected, screened','Recovered')
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% xlabel('Time (days)');
% ylabel('Number of patients');
figure
plot(x,countHospCol(:,[365:730],1), 'r', x, ...
countCS(:,[365:730],1), 'm', ...
x,countIN(:,[365:730],1), 'b', x, ...
countIS(:,[365:730],1), 'c')
legend('Hospital-onset, Colonized', ...
'Community-acquried, Colonized', 'Infected, not
tested', 'Infected, positive test')
xlabel('Time (days)');
ylabel('Number of patients');
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...

Appendix G

MATLAB CODE – T-TEST FOR ABM

% MUST RUN non-ADI model or ADI-model first
filename = '/Users/kellyreagan/Documents/Research/Cases
in BMT unit.xlsx';
T = readtable(filename);
data = T([1:77],2);
A = table2array(data);
% figure
% qqplot(A)
%
% figure
% histogram(A)

...

meanData = mean(A);
stdData = std(A);
varData = var(A);
simData = cumulative30DaySumInfected;
simData = simData';
simData = simData(:)';
simSample=datasample(simData,77);
simSample = simSample';
meanSim = mean(simSample);
stdSim = std(simSample);
varSim = var(simSample);
%figure
%histogram(simSample)
%
%
%
%

testing to see if variances are equal -- F-test
null hypothesis is that the variances are the same
alter hypothesis is that the variances are not
h =1 means reject the null hypothesis at the default ...
1% significance
% level
% ci contains the lower and upper boundaries of the 99% ...
confidence interval
% for the true variance ratio
%
124

[h,p,ci,stats]=vartest2(A,simSample, 'Alpha', 0.01)
%cannot reject the null hypothesis that the variances
are the same
%Now I can run a two sample t-test
[h2,p2,ci2,stats2]=ttest(A,simSample,'Alpha',0.01)

...

%returned value of h=0 indicates that I cannot reject
the null hypothesis

...
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